Lafora_Disease - dismech

👪

Inheritance

1

Autosomal recessive HP:0000007

Lafora disease follows autosomal recessive inheritance. EPM2A mutations account for approximately 50% of cases and NHLRC1 mutations for approximately 40-50%. Consanguineous families show higher incidence. Heterozygous carriers are asymptomatic.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:30143794 SUPPORT Human Clinical

"Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy."

Confirms autosomal recessive inheritance pattern for Lafora disease.

PMID:20538597 SUPPORT Model Organism

"Approximately 90% of cases of Lafora disease, a fatal teenage-onset progressive myoclonus epilepsy, are caused by mutations in either the EPM2A or the EPM2B genes that encode, respectively, a glycogen phosphatase called laforin and an E3 ubiquitin ligase called malin."

Confirms EPM2A and EPM2B as the two causative genes accounting for the vast majority of cases. This paper is a mouse knockout study of Epm2b.

◆

Subtypes

2

EPM2A-related Lafora disease MONDO:0958199

EPM2A link

Caused by biallelic loss-of-function mutations in EPM2A encoding laforin, a dual-specificity phosphatase with a carbohydrate-binding domain. Accounts for approximately 50% of cases.

Show evidence (1 reference)

PMID:11483392 SUPPORT Human Clinical

"Up to 80% of patients with Lafora's disease have mutations in the EPM2A gene."

Confirms EPM2A as a major causative gene. Note this early estimate of 80% was prior to NHLRC1 discovery.

NHLRC1-related Lafora disease MONDO:0800306

NHLRC1 link

Caused by biallelic loss-of-function mutations in NHLRC1 (also known as EPM2B) encoding malin, an E3 ubiquitin ligase that functions in complex with laforin. Accounts for approximately 40-50% of cases.

Show evidence (1 reference)

PMID:12958597 SUPPORT Human Clinical

"we identify a second gene associated with this disease, NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs."

Original discovery of NHLRC1/EPM2B as the second Lafora disease gene.

⚙

Pathophysiology

10

Loss of laforin glycogen phosphatase activity

Biallelic loss-of-function variants in EPM2A abolish laforin's dual-specificity glycogen phosphatase activity. Laforin normally binds glycogen via its carbohydrate-binding domain and dephosphorylates it; loss of this activity leads to glycogen hyperphosphorylation and, downstream, to abnormal chain length and insolubility. Laforin also serves as the glycogen-targeting subunit that recruits malin to glycogen, so its loss disrupts the laforin-malin complex at glycogen.

Neuron link Astrocyte link

Glycogen metabolic process link

protein tyrosine/threonine phosphatase activity link ↓ DECREASED carbohydrate binding link ↓ DECREASED

Downstream

Aberrant glycogen chain length and hyperphosphorylation Without laforin's phosphatase activity, glycogen accumulates phosphate groups and develops abnormal chain length patterns, driving precipitation into polyglucosans.

Loss of laforin-malin complex regulation of glycogen synthesis Because laforin is the carbohydrate-binding subunit that targets malin to glycogen, loss of laforin disengages malin from its glycogen substrate and disrupts ubiquitin-mediated regulation of glycogen synthesis machinery.

Show evidence (3 references)

PMID:30143794 SUPPORT Human Clinical

"The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."

Directly links loss of laforin/malin to hyperphosphorylated, poorly branched glycogen that forms Lafora bodies.

PMID:28536304 SUPPORT Model Organism

"We conclude that laforin's principle function is to control glycogen chain lengths, in a malin-dependent fashion, and that loss of this control underlies LD."

Demonstrates that laforin's primary functional role is malin-dependent control of glycogen chain length.

PMID:36511140 SUPPORT Model Organism

"malin localizes to glycogen, laforin and malin indeed interact, at glycogen, and malin's presence at glycogen depends on laforin."

Shows that laforin recruits malin to glycogen, so loss of laforin uncouples malin from its glycogen substrate.

Loss of laforin-malin complex regulation of glycogen synthesis

Malin (NHLRC1) is an E3 ubiquitin ligase that, in complex with laforin at glycogen, ubiquitinates substrates including PTG/PPP1R3C (a glycogen synthase activator) and glycogen synthase itself, restraining glycogen synthesis. Biallelic loss-of-function variants in NHLRC1, or loss of laforin (which targets malin to glycogen), inactivate this complex. Consequently, malin substrates such as PTG accumulate and drive excessive glycogen synthesis with abnormal architecture. Laforin also becomes sequestered in the insoluble polysaccharide fraction, where it is functionally inert.

Neuron link Astrocyte link

Protein ubiquitination link Glycogen biosynthetic process link

ubiquitin protein ligase activity link ↓ DECREASED

Downstream

PTG/glycogen synthase overactivation and excessive glycogen synthesis Without malin-mediated ubiquitination, PTG (PPP1R3C) and glycogen synthase are not appropriately restrained, leading to increased glycogen synthesis with overlong chains.

Aberrant glycogen chain length and hyperphosphorylation Loss of malin-laforin complex function permits accumulation of glycogen with abnormal chain length and elevated phosphate.

Show evidence (4 references)

PMID:12958597 SUPPORT Human Clinical

"NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs. Laforin and malin colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy."

Establishes malin as an E3 ubiquitin ligase operating with laforin to prevent polyglucosan accumulation.

PMID:20538597 SUPPORT Model Organism

"we conclude that malin functions to maintain laforin associated with soluble glycogen and that its absence causes sequestration of laforin to an insoluble polysaccharide fraction where it is functionally inert."

Demonstrates malin's role in maintaining laforin function and how its absence leads to functional inactivation of laforin.

PMID:30336494 SUPPORT Human Clinical

"Laforin and malin interact to regulate glycogen phosphorylation and chain length pattern, the latter critical to glycogen's solubility."

Confirms the functional interaction between laforin and malin in regulating glycogen structure.

+ 1 more reference

PTG/glycogen synthase overactivation and excessive glycogen synthesis

PTG (PPP1R3C) is a glycogen synthase activator that targets protein phosphatase 1 to glycogen. In normal cells, malin-mediated ubiquitination restrains PTG and glycogen synthase (GYS1) activity. With loss of laforin/malin function, PTG accumulates and a small pool of overactive GYS1 elongates glycogen chains beyond the threshold at which they remain soluble. Genetic depletion of PTG or constitutive/inducible knockout of GYS1 in mouse models prevents Lafora body formation and rescues seizure susceptibility, neurodegeneration, and behavioral abnormality, establishing GYS1-driven excessive glycogen synthesis as a critical and pharmacologically targetable node upstream of polyglucosan formation.

Astrocyte link Neuron link

Glycogen biosynthetic process link

glycogen synthase activity link ↑ INCREASED

Downstream

Aberrant glycogen chain length and hyperphosphorylation Unrestrained PTG-driven GYS1 activity produces glycogen with overlong chains that precipitate as polyglucosan.

Show evidence (4 references)

PMID:24419970 SUPPORT Model Organism

"reducing glycogen production in malin-deficient mice by genetically removing PTG, a glycogen synthesis activator protein, nearly completely eliminates Lafora bodies and rescues the neurodegeneration, myoclonus, seizure susceptibility, and behavioral abnormality."

Genetic PTG depletion in malin-deficient mice eliminates Lafora bodies and rescues neurological phenotypes, identifying PTG-driven glycogen synthesis as the critical drivable node.

PMID:39806098 SUPPORT Model Organism

"By depleting PTG, an activator of the glycogen chain-elongating enzyme glycogen synthase (GYS1), in laforin- and malin-deficient LD mice, we show that abnormal glycogen chain lengths and not hyperphosphorylation underlie polyglucosan formation, and that polyglucosan bodies induce neuroinflammation."

Confirms that PTG-driven GYS1 activity, not phosphate, generates polyglucosans and that the resulting Lafora bodies drive neuroinflammation.

PMID:39806098 SUPPORT Model Organism

"We provide evidence indicating that a small pool of overactive GYS1 contributes to glycogen insolubility in LD and APBD."

Demonstrates that overactive GYS1 (a small pool) is sufficient to drive glycogen insolubility in Lafora disease.

+ 1 more reference

Aberrant glycogen chain length and hyperphosphorylation

Combined loss of laforin's phosphatase activity and malin-mediated restraint on glycogen synthesis produces glycogen molecules with overlong glucan chains and elevated covalently-bound phosphate. Unlike normally branched soluble glycogen, these aberrant chains form double helices, extrude water, and precipitate. The resulting insoluble polyglucosan material progressively aggregates into Lafora bodies. Recent evidence indicates that abnormal chain length, more than hyperphosphorylation, is the proximal driver of insolubility.

Neuron link Astrocyte link

Glycogen metabolic process link

Downstream

Lafora body accumulation in neurons and astrocytes Insoluble, hyperphosphorylated, poorly branched glucan chains aggregate into intracellular Lafora bodies, predominantly in astrocytes and neurons of the cerebral and cerebellar cortex.

Poorly branched hyperphosphorylated glycogen Aberrant glycogen architecture is directly measured as poorly branched, hyperphosphorylated glycogen.

Polyglucosan chain length abnormality Overlong glycogen chains are the measurable chain-length component of the aberrant polyglucosan architecture.

Show evidence (3 references)

PMID:30143794 SUPPORT Human Clinical

"The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."

Confirms that the aberrant glycogen physically precipitates and aggregates as Lafora bodies.

PMID:29483193 SUPPORT Human Clinical

"Individuals with LD develop cytoplasmic, aberrant glycogen inclusions in nearly all tissues that more closely resemble plant starch than human glycogen."

Confirms the plant-starch-like (insoluble polyglucosan) nature of the inclusions.

PMID:39806098 SUPPORT Model Organism

"Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."

Defines the molecular nature of polyglucosans as overlong, hyperphosphorylated glycogen chains.

Lafora body accumulation in neurons and astrocytes

Insoluble polyglucosan material aggregates into discrete cytoplasmic Lafora bodies. Although classically described as neuronal, recent studies indicate that the majority of brain Lafora bodies are astrocytic, with distinct morphologies from neuronal perinuclear inclusions. Lafora bodies contain glycogen, ubiquitin, and proteostasis adaptors such as p62, and they are particularly enriched in cortical and hippocampal regions. Their accumulation drives downstream neuroinflammation, autophagic impairment, synaptic dysfunction, and neurodegeneration.

Astrocyte link Neuron link Pyramidal neuron link

Glycogen metabolic process link

Downstream

Reactive astrogliosis and neuroinflammation Lafora body accumulation, particularly in astrocytes, induces reactive astrogliosis and triggers a broad inflammatory transcriptional program.

Autophagy and mitophagy impairment Glycogen accumulation secondarily impairs macroautophagy and the autophagic clearance of damaged mitochondria.

Synaptic dysfunction and cortical hyperexcitability Lafora body accumulation in cortical neurons and perisynaptic astrocytes progressively disturbs synaptic function and shifts cortical networks toward sustained hyperexcitability.

Neurodegeneration Lafora body burden is a principal driver of progressive neurodegeneration in mouse models, validated by genetic rescue experiments.

Lafora body glycogen storage burden Lafora body accumulation is measured clinically and experimentally as an increased storage burden of insoluble glycogen-like inclusions.

Brain glycogen accumulation Brain Lafora body accumulation tracks the brain glycogen storage burden quantified in disease models.

Show evidence (3 references)

PMID:36899857 SUPPORT Model Organism

"most of these glycogen aggregates are present in astrocytes. Importantly, astrocytic Lafora bodies have been shown to contribute to pathology in Lafora disease."

Establishes astrocytes as the primary cell type harboring Lafora bodies and as contributors to disease pathology.

PMID:30143794 SUPPORT Model Organism

"Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."

Confirms Lafora bodies are not bystander inclusions but principal drivers of neurodegeneration.

PMID:24452334 SUPPORT Model Organism

"Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy."

Genetic rescue (malin-knockout x glycogen-synthesis-impaired) demonstrates that glycogen accumulation is the proximal cause of neurodegeneration and autophagy impairment.

Reactive astrogliosis and neuroinflammation

Astrocytic and neuronal Lafora bodies induce reactive astrogliosis and activate microglia. RNA-Seq of Epm2a-/- and Epm2b-/- mouse brains shows age-progressive upregulation of inflammatory mediators, dominated by TNF and IL-6/JAK2 signaling. Activation of a non-canonical inflammasome, elevated CXCL10 and S100B, miR-155/miR-146a upregulation, and infiltration of peripheral T-lymphocytes into brain parenchyma all contribute to a glia-driven inflammatory milieu. Sphingosine-1-phosphate receptor modulation (fingolimod) reduces this inflammation and improves behavior in Epm2b-/- mice, supporting causal contribution of neuroinflammation to disease severity.

Astrocyte link Microglial cell link

Neuroinflammatory response link Inflammatory response link

Downstream

Neurodegeneration Sustained glia-derived TNF/IL-6 signaling and infiltrating T-lymphocytes accelerate neuronal injury and loss.

Synaptic dysfunction and cortical hyperexcitability Reactive astrocytes lose normal synaptic support functions and release cytokines that shift cortical excitation/inhibition balance toward hyperexcitability.

Oxidative stress and proteostasis impairment Inflammatory signaling and reactive glia generate reactive oxygen species and disrupt proteostasis pathways.

Show evidence (3 references)

PMID:31808062 SUPPORT Model Organism

"in both models of LD, we found a common set of upregulated genes, most of them encoding mediators of inflammatory response; second, there was a progression with the age in the appearance of these inflammatory markers, starting at 3 months of age; and third, reactive glia was responsible for the..."

Defines reactive glia-derived neuroinflammation as a novel, age-progressive hallmark of Lafora disease in two independent mouse models.

PMID:36526090 SUPPORT Model Organism

"we define an upregulation of the expression of mediators of the TNF and IL6/JAK2 signaling pathways in LD. In addition, we describe the activation of the non-canonical form of the inflammasome. Furthermore, we describe the infiltration of peripheral immune cells in the brain parenchyma, which..."

Identifies TNF and IL-6/JAK2 as the dominant inflammatory pathways in Lafora disease, plus inflammasome activation and peripheral immune cell infiltration.

PMID:37971656 SUPPORT Model Organism

"Our results indicate a beneficial effect of fingolimod in reducing reactive astrogliosis-derived neuroinflammation and T-lymphocyte infiltration, which correlated with the improved behavioral performance of the treated Epm2b-/- mice."

Pharmacologic targeting of S1P signaling reduces reactive astrogliosis and T-cell infiltration with behavioral benefit, supporting causal role of neuroinflammation.

Oxidative stress and proteostasis impairment

Lafora disease brain shows elevated reactive oxygen species, altered miRNA profiles (miR-155 and miR-146a), and disrupted proteostasis. While autophagy impairment was once considered a primary driver, current evidence places oxidative stress and proteostasis disruption as age-progressive consequences of glycogen aggregation and neuroinflammation that nonetheless feed forward to neurodegeneration.

Neuron link Astrocyte link

Response to oxidative stress link

Downstream

Neurodegeneration Sustained oxidative damage and proteostasis failure compound neuroinflammatory injury and contribute to neuronal loss.

Show evidence (1 reference)

PMID:36674605 SUPPORT Model Organism

"Oxidative stress, alterations in proteostasis, and deregulation of inflammatory signals are some of the molecular alterations underlying this condition in both KO animal models."

Establishes oxidative stress and proteostasis impairment as recognized molecular features in both EPM2A and NHLRC1 mouse models.

Autophagy and mitophagy impairment

Glycogen accumulation in Lafora disease secondarily impairs macroautophagy and the selective autophagic degradation of damaged mitochondria (mitophagy). Genetic experiments show this autophagic impairment is rescued when glycogen synthesis is reduced, indicating it is downstream of glycogen aggregation rather than a primary defect. Mitophagy defects in patient fibroblasts manifest as reduced colocalization of mitochondrial and lysosomal markers despite intact upstream Parkin recruitment.

Neuron link Astrocyte link

Autophagy link Autophagy of mitochondrion link

Downstream

Neurodegeneration Defective autophagic clearance of damaged organelles and aggregates contributes to chronic neuronal injury.

Show evidence (2 references)

PMID:24452334 SUPPORT Model Organism

"the autophagy impairment that has been described in malin knockout animals was also rescued in this double knockout model."

Demonstrates that autophagy impairment is downstream of glycogen accumulation, since reducing glycogen synthesis rescues it.

PMID:29645350 SUPPORT In Vitro

"the autophagic degradation of altered mitochondria is impaired in LD, which is due to a partial defect in the autophagic response and not in the canonical mitophagy signalling pathways."

Demonstrates a partial mitophagy defect in Lafora disease patient fibroblasts at the level of the autophagic response.

Synaptic dysfunction and cortical hyperexcitability

Lafora body burden, perisynaptic astrocyte dysfunction, and inflammatory cytokines progressively destabilize cortical excitation/inhibition balance. Patients with Lafora body disease exhibit sustained sensorimotor cortex hyperexcitability with prolonged facilitation, consistent with severe impairment of inhibitory mechanisms. Hippocampal synaptic plasticity is disrupted in malin-knockout mice and is rescued when glycogen synthesis is reduced. The resulting hyperexcitability underlies the action and stimulus-sensitive myoclonus, photosensitive seizures, occipital (visual-hallucinatory) seizures, and progression to refractory epilepsy that defines the clinical syndrome.

Pyramidal neuron link Interneuron link Astrocyte link

Transmission of nerve impulse link Regulation of long-term neuronal synaptic plasticity link

Downstream

Myoclonus Sustained sensorimotor cortex hyperexcitability with impaired inhibition generates the action and stimulus-sensitive myoclonus that defines the progressive myoclonus epilepsy phenotype.

Seizures Cortical hyperexcitability and loss of inhibitory tone produce progressive epileptic seizures that become drug-resistant.

Generalized tonic-clonic seizures Cortical hyperexcitability supports generalization to bilateral tonic-clonic seizures.

Absence seizures Aberrant cortico-thalamic synchronization yields atypical and myoclonic absence seizures that become near-continuous as the disease progresses.

Visual hallucinations Occipital cortical hyperexcitability produces photosensitive epileptic visual hallucinations.

Photosensitive seizures Cortical hyperexcitability with impaired inhibition produces photoparoxysmal/photosensitive seizure responses.

Status epilepticus Loss of inhibitory control and progressive neurodegeneration culminate in episodes of status epilepticus, frequently lethal.

Atonic (drop) attacks Cortical network hyperexcitability also manifests as atonic and drop attacks that drive loss of ambulation.

Show evidence (3 references)

PMID:15623692 SUPPORT Human Clinical

"The LBD findings highlight sustained hyperexcitability of the sensorimotor cortex in response to afferent stimuli, which fit with a more severe impairment of inhibitory mechanisms."

Direct human electrophysiologic evidence that Lafora body disease features sustained cortical hyperexcitability with impaired inhibition.

PMID:24452334 SUPPORT Model Organism

"These animals did not show the increase in markers of neurodegeneration, the impairments in electrophysiological properties of hippocampal synapses, nor the susceptibility to kainate-induced epilepsy seen in the malin knockout model."

Genetic rescue of glycogen synthesis in malin-knockout mice restores hippocampal synaptic electrophysiology and abolishes kainate-induced seizure susceptibility, linking glycogen-driven synaptic dysfunction to epileptogenesis.

PMID:39806098 PARTIAL Model Organism

"polyglucosan bodies induce neuroinflammation"

Polyglucosan-induced neuroinflammation is implicated in the network excitability changes that drive seizures.

Neurodegeneration

Cumulative effects of Lafora body burden, neuroinflammation, oxidative stress, and autophagic impairment drive progressive neurodegeneration in cortex, hippocampus, and cerebellum. Cerebellar Purkinje cell involvement contributes to ataxia. Mouse models recapitulate this neurodegeneration, and genetic reduction of glycogen synthesis prevents it, identifying polyglucosan accumulation as the principal upstream driver. CHI3L1/YKL40 has emerged as a candidate biomarker of neurodegeneration in LD models.

Neuron link Pyramidal neuron link Purkinje cell link

Neuron apoptotic process link

Downstream

Progressive cognitive decline and dementia Cortical and hippocampal neuron loss produces relentless cognitive deterioration ending in profound dementia.

Ataxia Cerebellar neurodegeneration, including Purkinje cell involvement, contributes to ataxia.

Progressive neurologic deterioration Cumulative cortical and subcortical neuron loss underlies the relentless progression to a vegetative state.

Cerebral atrophy Cortical neuronal loss yields cerebral atrophy on neuroimaging in later disease.

Cerebellar atrophy Cerebellar neurodegeneration produces cerebellar atrophy.

Dysarthria Cortical and cerebellar neurodegeneration disrupts motor speech coordination.

Apraxia Cortical neurodegeneration produces apraxia.

Cortical visual impairment Occipital and association-cortex degeneration can progress from visual seizures and hallucinations to cortical visual loss.

Dysphagia Advanced neurologic deterioration impairs swallowing and secretion control, increasing aspiration risk.

Vegetative state End-stage cortical and subcortical neurodegeneration culminates in a vegetative state.

Neuropsychiatric symptoms Cortical dysfunction and progressive dementia produce behavioral and neuropsychiatric manifestations.

Show evidence (2 references)

PMID:30143794 SUPPORT Model Organism

"Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."

Establishes Lafora bodies as the principal upstream driver of neurodegeneration in genetic mouse models.

PMID:24452334 SUPPORT Model Organism

"Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy."

Genetic ablation of glycogen synthesis rescues neurodegeneration in malin knockout mice, establishing glycogen accumulation as proximal to neurodegeneration.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

19

Digestive 1

Dysphagia FREQUENT Dysphagia (HP:0002015)

Progressive bulbar dysfunction leads to dysphagia and aspiration risk in advanced disease. Gastrostomy feeding is recommended to reduce aspiration pneumonia, a common cause of death in late-stage Lafora disease.

Show evidence (1 reference)

PMID:20301563 SUPPORT Human Clinical

"Gastrostomy feedings can decrease the risk of aspiration pneumonia when the disease is advanced."

GeneReviews recommends gastrostomy in advanced disease to address dysphagia-related aspiration pneumonia risk.

Eye 1

Cortical visual impairment OCCASIONAL Visual impairment (HP:0000505)

Cortical blindness from advanced occipital and association cortex involvement; visual phenomena (hallucinations, scotomata) typically precede frank cortical visual loss.

Show evidence (1 reference)

PMID:29489177 SUPPORT Human Clinical

"Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."

Confirms cortical blindness as a characteristic late feature of Lafora disease.

Nervous System 13

Myoclonus VERY_FREQUENT Myoclonus (HP:0001336)

Action myoclonus and stimulus-sensitive myoclonus are prominent features, typically progressing from mild to intractable.

Show evidence (1 reference)

PMID:29489177 SUPPORT Human Clinical

"Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."

Confirms myoclonus as a characteristic and intractable feature of Lafora disease.

Seizures VERY_FREQUENT Seizure (HP:0001250)

Multiple seizure types including generalized tonic-clonic, myoclonic, absence, and visual (occipital) seizures. Seizures become increasingly refractory to treatment.

Show evidence (1 reference)

PMID:20527995 SUPPORT Human Clinical

"The condition is characterized by epilepsy, myoclonus and dementia."

Confirms seizures as one of the three cardinal features of Lafora disease.

Generalized tonic-clonic seizures VERY_FREQUENT Bilateral tonic-clonic seizure (HP:0002069)

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"Soon thereafter myoclonus appears and a generalized tonic-clonic seizure."

Confirms generalized tonic-clonic seizures as a presenting feature.

Absence seizures FREQUENT Generalized non-motor (absence) seizure (HP:0002121)

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"Atypical and myoclonic absences set in and then become so constant that the young patient’s every thought and sentence are constantly interrupted and incomplete."

Describes the progression of absence seizures becoming constant and severely disabling.

Visual hallucinations FREQUENT Visual hallucination (HP:0002367)

Occipital seizures with visual hallucinations are a characteristic early feature and may precede other seizure types.

Show evidence (2 references)

PMID:11483392 SUPPORT Human Clinical

"Characteristic seizures include myoclonic and occipital lobe seizures with visual hallucinations, scotomata, and photoconvulsions."

Confirms visual hallucinations from occipital seizures as a characteristic feature.

PMID:30336494 SUPPORT Human Clinical

"The patient commonly develops visual hallucinations, usually frightening which have been shown to be both epileptic and psychotic."

Confirms visual hallucinations as a common feature with both epileptic and psychotic components.

Progressive cognitive decline and dementia VERY_FREQUENT Dementia (HP:0000726)

Relentless cognitive deterioration beginning within a few years of seizure onset, progressing to severe dementia. Cognitive decline typically becomes apparent 2-5 years after seizure onset.

Show evidence (2 references)

PMID:11483392 SUPPORT Human Clinical

"The course of the disease consists of worsening seizures and an inexorable decline in mental and other neurologic functions that result in dementia and death within 10 years of onset."

Confirms progressive cognitive decline leading to dementia as a cardinal feature with a 10-year disease course.

PMID:36899857 SUPPORT Human Clinical

"the disease progresses rapidly with dementia, neuropsychiatric symptoms, and cognitive deterioration and has a fatal outcome within 5-10 years after onset."

Confirms rapid progression to dementia with fatal outcome within 5-10 years.

Progressive neurologic deterioration VERY_FREQUENT Progressive neurologic deterioration (HP:0002344)

Progressive neurological deterioration encompasses dysarthria, cerebellar ataxia, and cerebral atrophy visible on neuroimaging in later disease stages. These features develop as the disease advances toward a vegetative state.

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade."

Describes the progressive neurological deterioration culminating in a vegetative state.

Ataxia FREQUENT Ataxia (HP:0001251)

Show evidence (1 reference)

PMID:29489177 SUPPORT Human Clinical

"Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."

Confirms ataxia as a characteristic feature of Lafora disease.

Apraxia FREQUENT Apraxia (HP:0002186)

Show evidence (1 reference)

PMID:29489177 SUPPORT Human Clinical

"Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."

Confirms apraxia as a characteristic feature of Lafora disease.

Cerebral atrophy FREQUENT Cerebral atrophy (HP:0002059)

Generalized cortical atrophy is seen on neuroimaging in advancing disease, reflecting cumulative cortical neurodegeneration.

Show evidence (1 reference)

PMID:30143794 SUPPORT Model Organism

"Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."

Supports the neurodegenerative basis of cerebral atrophy seen in advancing disease.

Cerebellar atrophy OCCASIONAL Cerebellar atrophy (HP:0001272)

Cerebellar atrophy reflects Purkinje cell and cerebellar cortical neurodegeneration, contributing to ataxia and dysarthria in advancing disease.

Show evidence (1 reference)

PMID:30143794 PARTIAL Model Organism

"Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."

Indirect support; cerebellar atrophy is part of widespread Lafora-body-driven neurodegeneration.

Dysarthria FREQUENT Dysarthria (HP:0001260)

Progressive dysarthria emerges in mid-to-late disease, reflecting combined cerebellar and cortical motor neurodegeneration.

Show evidence (1 reference)

PMID:20301563 SUPPORT Human Clinical

"Dysarthria and ataxia appear early, while spasticity appears late."

GeneReviews entry for Lafora disease explicitly lists dysarthria as an early feature alongside ataxia.

Neuropsychiatric symptoms FREQUENT Atypical behavior (HP:0000708)

Behavioral abnormalities and neuropsychiatric symptoms (including disinhibited dementia, depression, and anxiety) emerge as Lafora disease progresses.

Show evidence (2 references)

PMID:29489177 SUPPORT Human Clinical

"Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."

Confirms neuropsychiatric symptoms as a characteristic feature of Lafora disease.

PMID:30336494 SUPPORT Human Clinical

"Behavioral abnormalities emerge, commonly in the realm of a disinhibited dementia."

Documents disinhibited dementia as the typical neuropsychiatric phenotype.

Other 4

Photosensitive seizures FREQUENT Photosensitive myoclonic seizure (HP:0001327)

Photoparoxysmal/photosensitive responses are characteristic on EEG and photoconvulsive seizures are commonly elicited.

Show evidence (2 references)

PMID:29489177 SUPPORT Human Clinical

"Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."

Confirms photosensitive seizures as a characteristic feature.

PMID:11483392 SUPPORT Human Clinical

"Characteristic seizures include myoclonic and occipital lobe seizures with visual hallucinations, scotomata, and photoconvulsions."

Describes photoconvulsions as part of the characteristic occipital seizure phenotype.

Status epilepticus FREQUENT Status epilepticus (HP:0002133)

Episodes of status epilepticus mark advanced disease, often follow dramatic loss of awareness, and are a common terminal event.

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"Most patients pass away in status epilepticus or from aspiration pneumonia secondary to neurological loss of the ability to control secretions."

Documents status epilepticus as a frequent terminal event in Lafora disease.

Atonic (drop) attacks FREQUENT Atonic seizure (HP:0010819)

Atonic and myoclonic-atonic attacks contribute substantially to loss of ambulation; affected patients are often unable to walk within a few years of onset because of frequent drop attacks.

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"Within a few years the patient is out of school and is unable to walk mainly because of frequent myoclonic and atonic attacks."

Documents the loss of ambulation due to myoclonic and atonic attacks.

Vegetative state VERY_FREQUENT Vegetative state (HP:0031358)

End-stage Lafora disease progresses to a vegetative state with little or no responsiveness; if airways are maintained patients can survive into early adulthood despite extensive Lafora body burden.

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade."

Documents progression to a vegetative state as the natural end-stage of disease.

🧬

Genetic Associations

2

EPM2A (Causative)

Show evidence (2 references)

PMID:37658439 SUPPORT Human Clinical

"The mutated gene was NHLRC1 in 56% and EPM2A in 44% of cases. 114 pathogenic variants (67 EPM2A; 47 NHLRC1) were identified."

Patient-level meta-analysis quantifying the relative contribution of EPM2A vs NHLRC1 in Lafora disease.

CGGV:assertion_f970ced6-0164-41ed-9e1f-1fb9f892bca6-2020-05-23T190000.000Z SUPPORT Other

ClinGen classifies the EPM2A-Lafora disease gene-disease relationship as definitive with autosomal recessive inheritance.

NHLRC1 (Causative)

Show evidence (4 references)

PMID:37658439 SUPPORT Human Clinical

"This study demonstrates the existence of prognostic genetic factors in LD, namely the genotype defined according to the functional impact of the pathogenic variants."

Establishes that the functional impact of NHLRC1/EPM2A variants is prognostically informative in Lafora disease.

PMID:37658439 SUPPORT Human Clinical

"The population carrying the homozygous p.Asp146Asn variant of NHLRC1 genotype was confirmed to have a more favourable prognosis in terms of disease duration."

Identifies homozygous NHLRC1 p.Asp146Asn as a favorable-prognosis genotype.

PMID:37658439 SUPPORT Human Clinical

"it may be speculated that malin plays a pivotal role in LD pathogenesis."

Authors interpret the worse prognosis with truncating NHLRC1 variants as evidence for malin's pivotal pathogenic role.

+ 1 more reference

💊

Treatments

7

Antiseizure medications

Action: Anticonvulsant agent therapy Ontology label: anticonvulsant agent therapy MAXO:0000167

Valproic acid, clonazepam, levetiracetam, perampanel, and zonisamide are used for seizure management but become progressively less effective as the disease advances. Sodium channel blockers (carbamazepine, phenytoin) may exacerbate myoclonus and should be avoided.

Show evidence (2 references)

PMID:30336494 SUPPORT Human Clinical

"Sodium channel blocking antiseizure medications, such as phenytoin worsen myoclonus and probably seizures but can be very beneficial in stopping status epilepticus."

Documents that sodium channel blockers worsen myoclonus while being useful for status epilepticus.

PMID:29489177 SUPPORT Human Clinical

"Antiepileptic drugs can be used for the management of myoclonus and seizures. However, patients can become drug-resistant over time, resulting in disease progression, increased seizure frequency, and a decline in neurologic function."

Confirms progressive drug resistance as a hallmark of the disease course.

Metformin

Action: Pharmacotherapy NCIT:C15986

Agent: metformin ↗

Metformin has been studied as a potential disease-modifying adjunct in Lafora disease, with model-organism data and an 18-patient observational follow-up suggesting slower clinical progression in treated patients.

Mechanism Target:

MODULATES Aberrant glycogen chain length and hyperphosphorylation — Metformin treatment reduced Lafora body formation and neurological abnormalities in Lafora disease mouse models and was associated with slower progression in treated patients, plausibly by reducing glycogen accumulation upstream of polyglucosan formation.

Show evidence (2 references)

PMID:36303102 SUPPORT Human Clinical

"Furthermore, we conducted a follow-up study of an initial cohort of 18 patients with Lafora disease, 8 treated with metformin and 10 untreated."

Documents the human Lafora disease cohort used to compare metformin-treated and untreated patients.

PMID:36303102 SUPPORT Human Clinical

"Moreover, patients receiving metformin had a slower progression of the disease."

Supports slower clinical progression in metformin-treated patients in the human follow-up cohort.

Supportive and palliative care

Action: Supportive care Ontology label: supportive care MAXO:0000950

As the disease progresses, management becomes primarily supportive and palliative, including nutritional support, physiotherapy, and management of complications such as aspiration pneumonia.

Show evidence (1 reference)

PMID:29489177 SUPPORT Human Clinical

"Management Lafora disease focuses on symptomatic relief of seizures and myoclonus, together with palliative, supportive, and rehabilitative measures."

Confirms palliative and supportive care as the mainstay of management.

Genetic counseling

Action: Genetic counseling Ontology label: genetic counseling MAXO:0000079

Genetic counseling is recommended for affected families to inform about recurrence risk (25% for each pregnancy when both parents are carriers), carrier testing, and prenatal diagnosis options. Counseling should now incorporate genotype-based prognostic information: biallelic protein-truncating variants in NHLRC1 are associated with worse survival (HR 2.88; 95% CI 1.23-6.78), while homozygous NHLRC1 p.Asp146Asn carries a more favorable prognosis.

Show evidence (2 references)

PMID:30143794 SUPPORT Human Clinical

"Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy."

Establishes the autosomal recessive inheritance pattern that drives the 25% per-pregnancy recurrence risk and motivates genetic counseling for carrier couples.

PMID:37658439 SUPPORT Human Clinical

"This study demonstrates the existence of prognostic genetic factors in LD, namely the genotype defined according to the functional impact of the pathogenic variants."

Justifies adding genotype-based prognostic counseling alongside standard recurrence-risk counseling.

Glycogen synthase 1 (GYS1) antisense oligonucleotide therapy (experimental)

Action: antisense oligonucleotide therapy Ontology label: Pharmacotherapy NCIT:C15986

Substrate reduction therapy using antisense oligonucleotides targeting GYS1 mRNA to lower brain glycogen synthesis and prevent Lafora body formation. Preclinical Gys1-ASO administration in Epm2b-/- mice reduced GYS1 protein, glycogen aggregation, Lafora body burden, and epileptiform discharges. ION283 (intrathecal ASO) is now in a Phase 1/2 clinical trial in patients aged 10-18 with genetically confirmed EPM2A or NHLRC1 disease (NCT06609889). This represents the first disease-modifying strategy advanced to clinical trials in Lafora disease.

Mechanism Target:

INHIBITS PTG/glycogen synthase overactivation and excessive glycogen synthesis — ASO-mediated reduction of GYS1 expression directly addresses the overactive glycogen synthesis node, halting polyglucosan/Lafora body accumulation in mouse models.

Show evidence (1 reference)

PMID:37700152 SUPPORT Model Organism

"an antisense oligonucleotide (ASO) was developed to reduce glycogen synthesis in the brain by targeting glycogen synthase 1 (Gys1)."

Establishes that the ASO mechanism is direct knockdown of GYS1, the overactive glycogen synthase node in the pathograph.

Show evidence (2 references)

PMID:37700152 SUPPORT Model Organism

"The mice treated with Gys1-ASO exhibited decreased Gys1 protein levels, decreased glycogen aggregation, and reduced epileptiform discharges compared to untreated Epm2b-/- mice."

Preclinical demonstration that Gys1-ASO reduces glycogen aggregation and epileptiform discharges in malin-deficient mice.

PMID:37700152 SUPPORT Model Organism

"This work provides proof of concept that a Gys1-ASO halts disease progression of EPM2B mutations of Lafora disease."

Establishes proof of concept that GYS1-ASO halts disease progression, supporting the rationale for ION283 clinical translation.

Perampanel

Action: Pharmacotherapy NCIT:C15986

Agent: perampanel ↗

Perampanel, a non-competitive AMPA receptor antagonist, has shown benefit on cortical action myoclonus and disability in case series of progressive myoclonic epilepsies including Lafora disease. It is one of the few add-on antiseizure medications with clinically observable benefit on the action myoclonus that defines disability in PMEs.

Show evidence (1 reference)

PMID:33841303 SUPPORT Human Clinical

"we are reporting the effectiveness of perampanel in five individuals affected by Unverricht-Lundborg disease, three by Lafora disease, two by sialidosis, and one by an undetermined PME."

Reports case-series effectiveness of perampanel in Lafora disease patients.

Ketogenic diet (experimental)

Action: dietary intervention MAXO:0000088

A restricted-carbohydrate ketogenic diet has been historically explored in advanced Lafora disease (NCT00007124). The hypothesis is that restricting carbohydrate substrate reduces brain glycogen synthesis and polyglucosan accumulation. The completed trial did not establish disease modification in advanced cases; the strategy remains of theoretical interest in newly diagnosed patients.

Show evidence (1 reference)

PMID:30336494 SUPPORT Human Clinical

"The ketogenic diet has been tried but without success, albeit in relatively advanced cases."

Documents the historical trial of ketogenic diet without disease-modifying success in advanced Lafora disease.

🔬

Biochemical Markers

4

Poorly branched hyperphosphorylated glycogen (ABNORMAL)

Context: Lafora disease produces qualitatively abnormal glycogen with poor branching, overlong chains, hyperphosphorylation, and reduced solubility. Because polyglucosan and hyperphosphorylated glycogen do not have more specific local CHEBI terms, this readout is anchored to glycogen with abnormal context.

Pathograph Readouts

Readout Of Aberrant glycogen chain length and hyperphosphorylation Positive Diagnostic

Detecting poorly branched, hyperphosphorylated glycogen reports the abnormal glycogen-architecture node upstream of Lafora body formation.

Show evidence (1 reference)

PMID:30143794 SUPPORT Human Clinical

"The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."

The abnormal glycogen species directly corresponds to the upstream glycogen-architecture mechanism.

Show evidence (1 reference)

PMID:30143794 SUPPORT Human Clinical

"The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."

This review links loss of laforin or malin to abnormal poorly branched, hyperphosphorylated glycogen.

Polyglucosan chain length abnormality (ABNORMAL)

Context: Polyglucosans in Lafora disease are glycogen molecules with overlong glucan chains. This readout separates abnormal chain length from total glycogen amount because chain length is the key determinant of insolubility in newer mechanistic studies.

Pathograph Readouts

Readout Of Aberrant glycogen chain length and hyperphosphorylation Positive Diagnostic

Overlong glycogen chains report the abnormal-chain-length component of the Lafora glycogen lesion.

Show evidence (1 reference)

PMID:39806098 SUPPORT Model Organism

"Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."

The paper defines Lafora polyglucosans by overlong glycogen chains, supporting chain-length abnormality as a mechanistic readout.

Show evidence (1 reference)

PMID:39806098 SUPPORT Model Organism

"Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."

Defines the polyglucosan storage material as abnormal glycogen with overlong chains and hyperphosphorylation.

Lafora body glycogen storage burden (INCREASED)

Context: Lafora bodies are insoluble, glycogen-like polyglucosan inclusions in neurons, astrocytes, skin sweat gland duct cells, and other tissues. Their presence is a diagnostic tissue readout of the disease storage lesion.

Pathograph Readouts

Readout Of Lafora body accumulation in neurons and astrocytes Positive Diagnostic

Increased Lafora body glycogen burden reports the intracellular storage node that drives downstream neuroinflammation and neurodegeneration.

Show evidence (1 reference)

PMID:29489177 SUPPORT Human Clinical

"The presence of the pathognomic Lafora bodies in a tissue biopsy is diagnostic of Lafora disease."

Diagnostic tissue detection of Lafora bodies supports this storage burden as a positive readout of the Lafora body accumulation node.

Show evidence (2 references)

PMID:29483193 SUPPORT Human Clinical

"Individuals with LD develop cytoplasmic, aberrant glycogen inclusions in nearly all tissues that more closely resemble plant starch than human glycogen."

Human Lafora disease is characterized by cytoplasmic aberrant glycogen inclusions in many tissues.

PMID:29489177 SUPPORT Human Clinical

"The presence of the pathognomic Lafora bodies in a tissue biopsy is diagnostic of Lafora disease."

Tissue biopsy evidence supports Lafora bodies as the diagnostic storage readout.

Brain glycogen accumulation (INCREASED)

Context: Experimental Lafora disease models quantify brain glycogen accumulation and insoluble glycogen-like Lafora bodies to monitor disease state and response to GYS1-lowering interventions.

Pathograph Readouts

Readout Of PTG/glycogen synthase overactivation and excessive glycogen synthesis Positive Monitoring

Increased brain glycogen reports excessive GYS1-driven glycogen synthesis and the storage burden produced by the overactive glycogen-synthesis node.

Show evidence (1 reference)

PMID:33277363 SUPPORT Model Organism

"Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."

Mouse-model evidence identifies glycogen accumulation and insoluble Lafora bodies as hallmark readouts of the synthesis-driven storage process.

Readout Of Lafora body accumulation in neurons and astrocytes Positive Monitoring

Brain glycogen accumulation tracks the storage burden that accumulates as insoluble Lafora bodies.

Show evidence (1 reference)

PMID:33277363 SUPPORT Model Organism

"Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."

Mouse-model evidence pairs glycogen accumulation with Lafora body formation as linked storage-burden readouts.

Show evidence (1 reference)

PMID:33277363 SUPPORT Model Organism

"Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."

Defines glycogen accumulation and Lafora body formation as hallmark biochemical findings in Lafora disease models.

🔬

Clinical Trials

3

NCT06609889 PHASE_I RECRUITING

A Phase 1/2 open-label study to evaluate the safety and efficacy of intrathecally administered ION283 (an antisense oligonucleotide targeting glycogen synthesis) in patients aged 10-18 years with genetically confirmed EPM2A or EPM2B/NHLRC1 Lafora disease. EEG biomarkers (background rhythms, sleep physiology, electrographic seizures, and epileptiform discharge counts) are used as efficacy endpoints over 2 years.

Target Phenotypes: Myoclonus ↗ Seizure ↗

Show evidence (1 reference)

clinicaltrials:NCT06609889 SUPPORT

"This study will test the safety and efficacy of multiple doses of ION283 administered as intrathecal (IT) injections by lumbar puncture (LP)."

First-in-human disease-modifying trial in Lafora disease using intrathecal ASO targeting glycogen synthesis.

NCT03876522 COMPLETED

Prospective, longitudinal, observational study of the natural history and functional status of patients with Lafora disease. Sponsored by Ionis Pharmaceuticals to define disease course, identify biomarkers, and establish outcome measures (Lafora Disease Performance Scale, seizure frequency, EEG, cognition, gait/ataxia, caregiver burden, blood/CSF biomarkers) for use in future treatment trials.

Show evidence (1 reference)

clinicaltrials:NCT03876522 SUPPORT

"A natural history and functional status study to characterize the clinical disease course in Lafora disease patients using standardized, quantitative evaluations and to identify useful biomarkers and clinical outcome measures for use in future Lafora treatment studies."

Defines outcome measures and biomarkers for the field, supporting design of subsequent disease-modifying trials.

NCT00007124 COMPLETED

Trial of a ketogenic diet in advanced Lafora disease, sponsored by NINDS. Tested whether a restricted-carbohydrate ketogenic diet could modify disease course in patients aged 10 years and older with histologically or genetically confirmed Lafora disease. Did not yield disease modification in advanced cases.

Show evidence (1 reference)

clinicaltrials:NCT00007124 SUPPORT

"This study will examine the effect of a restricted-carbohydrate diet (ketogenic diet) on Lafora disease-a severe neurological disease in which brain cells die because of abnormal accumulation of glucose (a type of sugar)."

NIH-sponsored trial of ketogenic diet in advanced Lafora disease.

{ }

Source YAML

click to show

name: Lafora_Disease
creation_date: '2026-03-08T00:00:00Z'
updated_date: '2026-05-21T19:45:22Z'
category: Mendelian
description: >
  Lafora disease is a rare, fatal form of progressive myoclonus epilepsy (PME type 2)
  with autosomal recessive inheritance, typically presenting in late childhood or
  adolescence (ages 12-17). It is caused by biallelic pathogenic variants in EPM2A
  (encoding laforin, a dual-specificity glycogen phosphatase) or NHLRC1/EPM2B (encoding
  malin, an E3 ubiquitin ligase). The hallmark pathological feature is the accumulation
  of Lafora bodies - insoluble, poorly branched polyglucosan inclusions - in neurons,
  astrocytes, and other tissues. The disease is characterized by progressive myoclonus,
  epileptic seizures (generalized tonic-clonic, absence, and occipital), visual
  hallucinations, and relentless cognitive decline leading to dementia and death within
  approximately 10 years of onset. There is currently no disease-modifying therapy.
references:
- reference: PMID:20301563
  title: Progressive Myoclonus Epilepsy, Lafora Type.
  tags:
  - GeneReviews
  findings: []
disease_term:
  preferred_term: Lafora disease
  term:
    id: MONDO:0009697
    label: Lafora disease
parents:
- Progressive Myoclonus Epilepsy
- Glycogen Storage Disease
prevalence:
- population: Global
  percentage: Rare
  notes: >
    Estimated prevalence approximately four cases per million globally, with
    higher frequency in Mediterranean countries, the Middle East, South Asia,
    and regions with higher rates of consanguinity. Population prevalence in
    Germany has been reported at 1.69 per 10 million.
  evidence:
  - reference: PMID:38137127
    reference_title: "Lafora disease: a case report and evolving treatment advancements."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lafora disease is a rare genetic disorder characterized by a disruption in glycogen metabolism. It manifests as progressive myoclonus epilepsy and cognitive decline during adolescence."
    explanation: Recent case-report/review describing the disease as rare; the same paper reports prevalence of approximately four per million.
progression:
- phase: Adolescent onset
  age_range: 12-17 years
  notes: >
    Previously healthy children present in adolescence with the first
    generalized tonic-clonic seizure, often preceded by vague school
    difficulties or headaches, and rapidly followed by myoclonus.
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The typical LD child presents in the approximate middle-third of the second decade of life with vague symptoms of headaches and school difficulties."
    explanation: Documents typical adolescent onset and prodromal presentation.
- phase: Progressive disability
  notes: >
    Within a few years of seizure onset patients are out of school and unable
    to walk because of frequent myoclonic and atonic attacks. Cognitive
    decline progresses to dementia and behavioral disinhibition. Awareness
    is maintained for up to a decade and is then lost, often dramatically
    following an episode of status epilepticus.
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Within a few years the patient is out of school and is unable to walk mainly because of frequent myoclonic and atonic attacks."
    explanation: Documents the trajectory from initial seizures to loss of independent ambulation within a few years.
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Awareness is maintained for up to a decade but is then lost often dramatically following an attack of status epilepticus."
    explanation: Documents the clinical inflection point at which awareness is lost.
- phase: End-stage / fatal outcome
  duration: 5-10 years from onset
  notes: >
    Patients progress to a vegetative state and die within approximately
    a decade, typically from status epilepticus or aspiration pneumonia.
    Survival can extend into the early forties with attentive airway and
    feeding management.
  evidence:
  - reference: PMID:11483392
    reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The course of the disease consists of worsening seizures and an inexorable decline in mental and other neurologic functions that result in dementia and death within 10 years of onset."
    explanation: Establishes the canonical 10-year disease course from onset to death.
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients pass away in status epilepticus or from aspiration pneumonia secondary to neurological loss of the ability to control secretions."
    explanation: Documents the typical terminal events.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Lafora disease follows autosomal recessive inheritance. EPM2A mutations
    account for approximately 50% of cases and NHLRC1 mutations for approximately
    40-50%. Consanguineous families show higher incidence. Heterozygous carriers
    are asymptomatic.
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy."
    explanation: Confirms autosomal recessive inheritance pattern for Lafora disease.
  - reference: PMID:20538597
    reference_title: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Approximately 90% of cases of Lafora disease, a fatal teenage-onset progressive myoclonus epilepsy, are caused by mutations in either the EPM2A or the EPM2B genes that encode, respectively, a glycogen phosphatase called laforin and an E3 ubiquitin ligase called malin."
    explanation: Confirms EPM2A and EPM2B as the two causative genes accounting for the vast majority of cases. This paper is a mouse knockout study of Epm2b.
has_subtypes:
- name: EPM2A-related Lafora disease
  description: >
    Caused by biallelic loss-of-function mutations in EPM2A encoding laforin,
    a dual-specificity phosphatase with a carbohydrate-binding domain.
    Accounts for approximately 50% of cases.
  subtype_term:
    preferred_term: myoclonic epilepsy of Lafora 1
    term:
      id: MONDO:0958199
      label: myoclonic epilepsy of Lafora 1
  genes:
  - preferred_term: EPM2A
    description: Laforin, a dual-specificity glycogen phosphatase
    term:
      id: hgnc:3413
      label: EPM2A
  evidence:
  - reference: PMID:11483392
    reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Up to 80% of patients with Lafora's disease have mutations in the EPM2A gene."
    explanation: Confirms EPM2A as a major causative gene. Note this early estimate of 80% was prior to NHLRC1 discovery.
- name: NHLRC1-related Lafora disease
  description: >
    Caused by biallelic loss-of-function mutations in NHLRC1 (also known as
    EPM2B) encoding malin, an E3 ubiquitin ligase that functions in complex
    with laforin. Accounts for approximately 40-50% of cases.
  subtype_term:
    preferred_term: myoclonic epilepsy of Lafora 2
    term:
      id: MONDO:0800306
      label: myoclonic epilepsy of Lafora 2
  genes:
  - preferred_term: NHLRC1
    description: Malin, an E3 ubiquitin ligase
    term:
      id: hgnc:21576
      label: NHLRC1
  evidence:
  - reference: PMID:12958597
    reference_title: "Mutations in NHLRC1 cause progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identify a second gene associated with this disease, NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs."
    explanation: Original discovery of NHLRC1/EPM2B as the second Lafora disease gene.
pathophysiology:
- name: Loss of laforin glycogen phosphatase activity
  description: >
    Biallelic loss-of-function variants in EPM2A abolish laforin's dual-specificity
    glycogen phosphatase activity. Laforin normally binds glycogen via its
    carbohydrate-binding domain and dephosphorylates it; loss of this activity
    leads to glycogen hyperphosphorylation and, downstream, to abnormal chain
    length and insolubility. Laforin also serves as the glycogen-targeting
    subunit that recruits malin to glycogen, so its loss disrupts the
    laforin-malin complex at glycogen.
  gene:
    preferred_term: EPM2A
    description: Laforin, a dual-specificity glycogen phosphatase
    modifier: DECREASED
    term:
      id: hgnc:3413
      label: EPM2A
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Glycogen metabolic process
    term:
      id: GO:0005977
      label: glycogen metabolic process
  molecular_functions:
  - preferred_term: protein tyrosine/threonine phosphatase activity
    term:
      id: GO:0008330
      label: protein tyrosine/threonine phosphatase activity
    modifier: DECREASED
  - preferred_term: carbohydrate binding
    term:
      id: GO:0030246
      label: carbohydrate binding
    modifier: DECREASED
  chemical_entities:
  - preferred_term: glycogen
    term:
      id: CHEBI:28087
      label: glycogen
    modifier: ABNORMAL
  downstream:
  - target: Aberrant glycogen chain length and hyperphosphorylation
    description: >
      Without laforin's phosphatase activity, glycogen accumulates phosphate
      groups and develops abnormal chain length patterns, driving precipitation
      into polyglucosans.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - loss of glycogen phosphatase activity
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
      explanation: Loss of laforin or malin produces the abnormal glycogen species modeled by this downstream node.
  - target: Loss of laforin-malin complex regulation of glycogen synthesis
    description: >
      Because laforin is the carbohydrate-binding subunit that targets malin
      to glycogen, loss of laforin disengages malin from its glycogen substrate
      and disrupts ubiquitin-mediated regulation of glycogen synthesis machinery.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36511140
      reference_title: "Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "malin localizes to glycogen, laforin and malin indeed interact, at glycogen, and malin's presence at glycogen depends on laforin."
      explanation: Laforin directly recruits malin to glycogen, so laforin loss disrupts the laforin-malin regulatory complex.
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
    explanation: Directly links loss of laforin/malin to hyperphosphorylated, poorly branched glycogen that forms Lafora bodies.
  - reference: PMID:28536304
    reference_title: "Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We conclude that laforin's principle function is to control glycogen chain lengths, in a malin-dependent fashion, and that loss of this control underlies LD."
    explanation: Demonstrates that laforin's primary functional role is malin-dependent control of glycogen chain length.
  - reference: PMID:36511140
    reference_title: "Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "malin localizes to glycogen, laforin and malin indeed interact, at glycogen, and malin's presence at glycogen depends on laforin."
    explanation: Shows that laforin recruits malin to glycogen, so loss of laforin uncouples malin from its glycogen substrate.
- name: Loss of laforin-malin complex regulation of glycogen synthesis
  description: >
    Malin (NHLRC1) is an E3 ubiquitin ligase that, in complex with laforin at
    glycogen, ubiquitinates substrates including PTG/PPP1R3C (a glycogen
    synthase activator) and glycogen synthase itself, restraining glycogen
    synthesis. Biallelic loss-of-function variants in NHLRC1, or loss of
    laforin (which targets malin to glycogen), inactivate this complex.
    Consequently, malin substrates such as PTG accumulate and drive excessive
    glycogen synthesis with abnormal architecture. Laforin also becomes
    sequestered in the insoluble polysaccharide fraction, where it is
    functionally inert.
  gene:
    preferred_term: NHLRC1
    description: Malin, an E3 ubiquitin ligase that partners with laforin
    modifier: DECREASED
    term:
      id: hgnc:21576
      label: NHLRC1
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Protein ubiquitination
    term:
      id: GO:0016567
      label: protein ubiquitination
  - preferred_term: Glycogen biosynthetic process
    term:
      id: GO:0005978
      label: glycogen biosynthetic process
  molecular_functions:
  - preferred_term: ubiquitin protein ligase activity
    term:
      id: GO:0061630
      label: ubiquitin protein ligase activity
    modifier: DECREASED
  chemical_entities:
  - preferred_term: glycogen
    term:
      id: CHEBI:28087
      label: glycogen
    modifier: ABNORMAL
  downstream:
  - target: PTG/glycogen synthase overactivation and excessive glycogen synthesis
    description: >
      Without malin-mediated ubiquitination, PTG (PPP1R3C) and glycogen synthase
      are not appropriately restrained, leading to increased glycogen synthesis
      with overlong chains.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - loss of malin-mediated ubiquitination
    evidence:
    - reference: PMID:12958597
      reference_title: "Mutations in NHLRC1 cause progressive myoclonus epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs. Laforin and malin colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy."
      explanation: Malin is an E3 ubiquitin ligase operating with laforin to protect against polyglucosan accumulation and epilepsy.
  - target: Aberrant glycogen chain length and hyperphosphorylation
    description: >
      Loss of malin-laforin complex function permits accumulation of glycogen
      with abnormal chain length and elevated phosphate.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Laforin and malin interact to regulate glycogen phosphorylation and chain length pattern, the latter critical to glycogen's solubility."
      explanation: The review directly connects laforin-malin complex function to glycogen phosphorylation and chain-length regulation.
  evidence:
  - reference: PMID:12958597
    reference_title: "Mutations in NHLRC1 cause progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NHLRC1 (also called EPM2B), which encodes malin, a putative E3 ubiquitin ligase with a RING finger domain and six NHL motifs. Laforin and malin colocalize to the ER, suggesting they operate in a related pathway protecting against polyglucosan accumulation and epilepsy."
    explanation: Establishes malin as an E3 ubiquitin ligase operating with laforin to prevent polyglucosan accumulation.
  - reference: PMID:20538597
    reference_title: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we conclude that malin functions to maintain laforin associated with soluble glycogen and that its absence causes sequestration of laforin to an insoluble polysaccharide fraction where it is functionally inert."
    explanation: Demonstrates malin's role in maintaining laforin function and how its absence leads to functional inactivation of laforin.
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laforin and malin interact to regulate glycogen phosphorylation and chain length pattern, the latter critical to glycogen's solubility."
    explanation: Confirms the functional interaction between laforin and malin in regulating glycogen structure.
  - reference: PMID:28536304
    reference_title: "Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "general impairment of autophagy is not necessary in LD"
    explanation: Demonstrates that autophagy impairment is not a necessary component of Lafora disease pathogenesis, challenging the hypothesis that autophagy disruption is a primary driver.
- name: PTG/glycogen synthase overactivation and excessive glycogen synthesis
  description: >
    PTG (PPP1R3C) is a glycogen synthase activator that targets protein
    phosphatase 1 to glycogen. In normal cells, malin-mediated ubiquitination
    restrains PTG and glycogen synthase (GYS1) activity. With loss of
    laforin/malin function, PTG accumulates and a small pool of overactive
    GYS1 elongates glycogen chains beyond the threshold at which they remain
    soluble. Genetic depletion of PTG or constitutive/inducible knockout of
    GYS1 in mouse models prevents Lafora body formation and rescues seizure
    susceptibility, neurodegeneration, and behavioral abnormality, establishing
    GYS1-driven excessive glycogen synthesis as a critical and pharmacologically
    targetable node upstream of polyglucosan formation.
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Glycogen biosynthetic process
    term:
      id: GO:0005978
      label: glycogen biosynthetic process
  molecular_functions:
  - preferred_term: glycogen synthase activity
    term:
      id: GO:0004373
      label: alpha-1,4-glucan glucosyltransferase (UDP-glucose donor) activity
    modifier: INCREASED
  downstream:
  - target: Aberrant glycogen chain length and hyperphosphorylation
    description: >
      Unrestrained PTG-driven GYS1 activity produces glycogen with overlong
      chains that precipitate as polyglucosan.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39806098
      reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "By depleting PTG, an activator of the glycogen chain-elongating enzyme glycogen synthase (GYS1), in laforin- and malin-deficient LD mice, we show that abnormal glycogen chain lengths and not hyperphosphorylation underlie polyglucosan formation, and that polyglucosan bodies induce neuroinflammation."
      explanation: PTG depletion (which normalizes GYS1 activity) prevents abnormal chain length, establishing the directionality of this causal edge.
  evidence:
  - reference: PMID:24419970
    reference_title: "PTG protein depletion rescues malin-deficient Lafora disease in mouse."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "reducing glycogen production in malin-deficient mice by genetically removing PTG, a glycogen synthesis activator protein, nearly completely eliminates Lafora bodies and rescues the neurodegeneration, myoclonus, seizure susceptibility, and behavioral abnormality."
    explanation: Genetic PTG depletion in malin-deficient mice eliminates Lafora bodies and rescues neurological phenotypes, identifying PTG-driven glycogen synthesis as the critical drivable node.
  - reference: PMID:39806098
    reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "By depleting PTG, an activator of the glycogen chain-elongating enzyme glycogen synthase (GYS1), in laforin- and malin-deficient LD mice, we show that abnormal glycogen chain lengths and not hyperphosphorylation underlie polyglucosan formation, and that polyglucosan bodies induce neuroinflammation."
    explanation: Confirms that PTG-driven GYS1 activity, not phosphate, generates polyglucosans and that the resulting Lafora bodies drive neuroinflammation.
  - reference: PMID:39806098
    reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We provide evidence indicating that a small pool of overactive GYS1 contributes to glycogen insolubility in LD and APBD."
    explanation: Demonstrates that overactive GYS1 (a small pool) is sufficient to drive glycogen insolubility in Lafora disease.
  - reference: PMID:33277363
    reference_title: "An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Constitutive reduction of glycogen synthase-1 (GYS1) activity prevents murine LD"
    explanation: Confirms that genetic reduction of GYS1 activity prevents Lafora disease in murine models, establishing GYS1 as a tractable therapeutic target.
- name: Aberrant glycogen chain length and hyperphosphorylation
  description: >
    Combined loss of laforin's phosphatase activity and malin-mediated
    restraint on glycogen synthesis produces glycogen molecules with overlong
    glucan chains and elevated covalently-bound phosphate. Unlike normally
    branched soluble glycogen, these aberrant chains form double helices,
    extrude water, and precipitate. The resulting insoluble polyglucosan
    material progressively aggregates into Lafora bodies. Recent evidence
    indicates that abnormal chain length, more than hyperphosphorylation,
    is the proximal driver of insolubility.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Glycogen metabolic process
    term:
      id: GO:0005977
      label: glycogen metabolic process
  chemical_entities:
  - preferred_term: poorly branched hyperphosphorylated glycogen
    term:
      id: CHEBI:28087
      label: glycogen
    modifier: ABNORMAL
  downstream:
  - target: Lafora body accumulation in neurons and astrocytes
    description: >
      Insoluble, hyperphosphorylated, poorly branched glucan chains aggregate
      into intracellular Lafora bodies, predominantly in astrocytes and
      neurons of the cerebral and cerebellar cortex.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
      explanation: Abnormal glycogen precipitation and aggregation directly produces Lafora bodies.
  - target: Poorly branched hyperphosphorylated glycogen
    description: >
      Aberrant glycogen architecture is directly measured as poorly branched,
      hyperphosphorylated glycogen.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
      explanation: This biochemical readout is the abnormal glycogen species described in the mechanism.
  - target: Polyglucosan chain length abnormality
    description: >
      Overlong glycogen chains are the measurable chain-length component of
      the aberrant polyglucosan architecture.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39806098
      reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."
      explanation: This directly supports chain-length abnormality as a readout of the aberrant glycogen node.
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
    explanation: Confirms that the aberrant glycogen physically precipitates and aggregates as Lafora bodies.
  - reference: PMID:29483193
    reference_title: "Lafora disease offers a unique window into neuronal glycogen metabolism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with LD develop cytoplasmic, aberrant glycogen inclusions in nearly all tissues that more closely resemble plant starch than human glycogen."
    explanation: Confirms the plant-starch-like (insoluble polyglucosan) nature of the inclusions.
  - reference: PMID:39806098
    reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."
    explanation: Defines the molecular nature of polyglucosans as overlong, hyperphosphorylated glycogen chains.
- name: Lafora body accumulation in neurons and astrocytes
  description: >
    Insoluble polyglucosan material aggregates into discrete cytoplasmic
    Lafora bodies. Although classically described as neuronal, recent studies
    indicate that the majority of brain Lafora bodies are astrocytic, with
    distinct morphologies from neuronal perinuclear inclusions. Lafora bodies
    contain glycogen, ubiquitin, and proteostasis adaptors such as p62, and
    they are particularly enriched in cortical and hippocampal regions.
    Their accumulation drives downstream neuroinflammation, autophagic
    impairment, synaptic dysfunction, and neurodegeneration.
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  biological_processes:
  - preferred_term: Glycogen metabolic process
    term:
      id: GO:0005977
      label: glycogen metabolic process
  chemical_entities:
  - preferred_term: polyglucosan/Lafora-body glycogen
    term:
      id: CHEBI:28087
      label: glycogen
    modifier: INCREASED
  downstream:
  - target: Reactive astrogliosis and neuroinflammation
    description: >
      Lafora body accumulation, particularly in astrocytes, induces reactive
      astrogliosis and triggers a broad inflammatory transcriptional program.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39806098
      reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "polyglucosan bodies induce neuroinflammation"
      explanation: Direct experimental evidence that polyglucosan body formation causally induces neuroinflammation.
  - target: Autophagy and mitophagy impairment
    description: >
      Glycogen accumulation secondarily impairs macroautophagy and the
      autophagic clearance of damaged mitochondria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - intracellular glycogen aggregate burden disrupting autophagic flux
    evidence:
    - reference: PMID:24452334
      reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "the autophagy impairment that has been described in malin knockout animals was also rescued in this double knockout model."
      explanation: Genetic rescue (reducing glycogen synthesis) rescues autophagy impairment, establishing the directionality of this edge.
  - target: Synaptic dysfunction and cortical hyperexcitability
    description: >
      Lafora body accumulation in cortical neurons and perisynaptic astrocytes
      progressively disturbs synaptic function and shifts cortical networks
      toward sustained hyperexcitability.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - glycogen-driven hippocampal synaptic electrophysiologic impairment
    evidence:
    - reference: PMID:24452334
      reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These animals did not show the increase in markers of neurodegeneration, the impairments in electrophysiological properties of hippocampal synapses, nor the susceptibility to kainate-induced epilepsy seen in the malin knockout model."
      explanation: Reducing glycogen accumulation rescues hippocampal synaptic electrophysiology and seizure susceptibility, establishing that glycogen-driven Lafora body accumulation causes the synaptic dysfunction.
  - target: Neurodegeneration
    description: >
      Lafora body burden is a principal driver of progressive neurodegeneration
      in mouse models, validated by genetic rescue experiments.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neuroinflammation
    - autophagy impairment
    - synaptic dysfunction
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
      explanation: Direct attribution of neurodegeneration to Lafora body inclusions in genetic mouse models.
  - target: Lafora body glycogen storage burden
    description: >
      Lafora body accumulation is measured clinically and experimentally as an
      increased storage burden of insoluble glycogen-like inclusions.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29489177
      reference_title: "Lafora Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The presence of the pathognomic Lafora bodies in a tissue biopsy is diagnostic of Lafora disease."
      explanation: Tissue detection of Lafora bodies directly reports Lafora body storage burden.
  - target: Brain glycogen accumulation
    description: >
      Brain Lafora body accumulation tracks the brain glycogen storage burden
      quantified in disease models.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33277363
      reference_title: "An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."
      explanation: Glycogen accumulation and Lafora body formation are paired storage-burden readouts in the mouse model.
  evidence:
  - reference: PMID:36899857
    reference_title: "Role of Astrocytes in the Pathophysiology of Lafora Disease and Other Glycogen Storage Disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "most of these glycogen aggregates are present in astrocytes. Importantly, astrocytic Lafora bodies have been shown to contribute to pathology in Lafora disease."
    explanation: Establishes astrocytes as the primary cell type harboring Lafora bodies and as contributors to disease pathology.
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
    explanation: Confirms Lafora bodies are not bystander inclusions but principal drivers of neurodegeneration.
  - reference: PMID:24452334
    reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy."
    explanation: Genetic rescue (malin-knockout x glycogen-synthesis-impaired) demonstrates that glycogen accumulation is the proximal cause of neurodegeneration and autophagy impairment.
- name: Reactive astrogliosis and neuroinflammation
  description: >
    Astrocytic and neuronal Lafora bodies induce reactive astrogliosis and
    activate microglia. RNA-Seq of Epm2a-/- and Epm2b-/- mouse brains shows
    age-progressive upregulation of inflammatory mediators, dominated by
    TNF and IL-6/JAK2 signaling. Activation of a non-canonical inflammasome,
    elevated CXCL10 and S100B, miR-155/miR-146a upregulation, and infiltration
    of peripheral T-lymphocytes into brain parenchyma all contribute to a
    glia-driven inflammatory milieu. Sphingosine-1-phosphate receptor
    modulation (fingolimod) reduces this inflammation and improves behavior
    in Epm2b-/- mice, supporting causal contribution of neuroinflammation to
    disease severity.
  cell_types:
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: Microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Neurodegeneration
    description: >
      Sustained glia-derived TNF/IL-6 signaling and infiltrating
      T-lymphocytes accelerate neuronal injury and loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - TNF and IL6/JAK2 signaling
    - T-lymphocyte infiltration
    evidence:
    - reference: PMID:36526090
      reference_title: "TNF and IL6/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "we define an upregulation of the expression of mediators of the TNF and IL6/JAK2 signaling pathways in LD. In addition, we describe the activation of the non-canonical form of the inflammasome. Furthermore, we describe the infiltration of peripheral immune cells in the brain parenchyma, which could aggravate glia-derived neuroinflammation."
      explanation: The inflammatory pathways and infiltrating immune cells provide intermediates linking neuroinflammation to neuronal injury.
  - target: Synaptic dysfunction and cortical hyperexcitability
    description: >
      Reactive astrocytes lose normal synaptic support functions and release
      cytokines that shift cortical excitation/inhibition balance toward
      hyperexcitability.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37971656
      reference_title: "Beneficial Effect of Fingolimod in a Lafora Disease Mouse Model by Preventing Reactive Astrogliosis-Derived Neuroinflammation and Brain Infiltration of T-lymphocytes."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our results indicate a beneficial effect of fingolimod in reducing reactive astrogliosis-derived neuroinflammation and T-lymphocyte infiltration, which correlated with the improved behavioral performance of the treated Epm2b-/- mice."
      explanation: Reducing reactive astrogliosis-derived neuroinflammation improves behavior in the mouse model, supporting its contribution to downstream network dysfunction.
  - target: Oxidative stress and proteostasis impairment
    description: >
      Inflammatory signaling and reactive glia generate reactive oxygen
      species and disrupt proteostasis pathways.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - inflammatory signaling
    evidence:
    - reference: PMID:36674605
      reference_title: "Age-Related microRNA Overexpression in Lafora Disease Male Mice Provides Links between Neuroinflammation and Oxidative Stress."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Oxidative stress, alterations in proteostasis, and deregulation of inflammatory signals are some of the molecular alterations underlying this condition in both KO animal models."
      explanation: The mouse study connects inflammatory-signal deregulation with oxidative stress and proteostasis alterations in Lafora models.
  evidence:
  - reference: PMID:31808062
    reference_title: "Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "in both models of LD, we found a common set of upregulated genes, most of them encoding mediators of inflammatory response; second, there was a progression with the age in the appearance of these inflammatory markers, starting at 3 months of age; and third, reactive glia was responsible for the expression of these inflammatory genes."
    explanation: Defines reactive glia-derived neuroinflammation as a novel, age-progressive hallmark of Lafora disease in two independent mouse models.
  - reference: PMID:36526090
    reference_title: "TNF and IL6/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we define an upregulation of the expression of mediators of the TNF and IL6/JAK2 signaling pathways in LD. In addition, we describe the activation of the non-canonical form of the inflammasome. Furthermore, we describe the infiltration of peripheral immune cells in the brain parenchyma, which could aggravate glia-derived neuroinflammation."
    explanation: Identifies TNF and IL-6/JAK2 as the dominant inflammatory pathways in Lafora disease, plus inflammasome activation and peripheral immune cell infiltration.
  - reference: PMID:37971656
    reference_title: "Beneficial Effect of Fingolimod in a Lafora Disease Mouse Model by Preventing Reactive Astrogliosis-Derived Neuroinflammation and Brain Infiltration of T-lymphocytes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results indicate a beneficial effect of fingolimod in reducing reactive astrogliosis-derived neuroinflammation and T-lymphocyte infiltration, which correlated with the improved behavioral performance of the treated Epm2b-/- mice."
    explanation: Pharmacologic targeting of S1P signaling reduces reactive astrogliosis and T-cell infiltration with behavioral benefit, supporting causal role of neuroinflammation.
- name: Oxidative stress and proteostasis impairment
  description: >
    Lafora disease brain shows elevated reactive oxygen species, altered
    miRNA profiles (miR-155 and miR-146a), and disrupted proteostasis. While
    autophagy impairment was once considered a primary driver, current
    evidence places oxidative stress and proteostasis disruption as
    age-progressive consequences of glycogen aggregation and neuroinflammation
    that nonetheless feed forward to neurodegeneration.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  downstream:
  - target: Neurodegeneration
    description: >
      Sustained oxidative damage and proteostasis failure compound
      neuroinflammatory injury and contribute to neuronal loss.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36674605
      reference_title: "Age-Related microRNA Overexpression in Lafora Disease Male Mice Provides Links between Neuroinflammation and Oxidative Stress."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Oxidative stress, alterations in proteostasis, and deregulation of inflammatory signals are some of the molecular alterations underlying this condition in both KO animal models."
      explanation: Oxidative stress and proteostasis alterations are molecular disease features that contribute to downstream neuronal injury.
  evidence:
  - reference: PMID:36674605
    reference_title: "Age-Related microRNA Overexpression in Lafora Disease Male Mice Provides Links between Neuroinflammation and Oxidative Stress."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Oxidative stress, alterations in proteostasis, and deregulation of inflammatory signals are some of the molecular alterations underlying this condition in both KO animal models."
    explanation: Establishes oxidative stress and proteostasis impairment as recognized molecular features in both EPM2A and NHLRC1 mouse models.
- name: Autophagy and mitophagy impairment
  description: >
    Glycogen accumulation in Lafora disease secondarily impairs macroautophagy
    and the selective autophagic degradation of damaged mitochondria
    (mitophagy). Genetic experiments show this autophagic impairment is
    rescued when glycogen synthesis is reduced, indicating it is downstream
    of glycogen aggregation rather than a primary defect. Mitophagy defects
    in patient fibroblasts manifest as reduced colocalization of mitochondrial
    and lysosomal markers despite intact upstream Parkin recruitment.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: Autophagy of mitochondrion
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
  downstream:
  - target: Neurodegeneration
    description: >
      Defective autophagic clearance of damaged organelles and aggregates
      contributes to chronic neuronal injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:24452334
      reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy."
      explanation: Genetic rescue evidence links glycogen-driven autophagy impairment with neurodegeneration and functional consequences.
  evidence:
  - reference: PMID:24452334
    reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the autophagy impairment that has been described in malin knockout animals was also rescued in this double knockout model."
    explanation: Demonstrates that autophagy impairment is downstream of glycogen accumulation, since reducing glycogen synthesis rescues it.
  - reference: PMID:29645350
    reference_title: "Degradation of altered mitochondria by autophagy is impaired in Lafora disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "the autophagic degradation of altered mitochondria is impaired in LD, which is due to a partial defect in the autophagic response and not in the canonical mitophagy signalling pathways."
    explanation: Demonstrates a partial mitophagy defect in Lafora disease patient fibroblasts at the level of the autophagic response.
- name: Synaptic dysfunction and cortical hyperexcitability
  description: >
    Lafora body burden, perisynaptic astrocyte dysfunction, and inflammatory
    cytokines progressively destabilize cortical excitation/inhibition balance.
    Patients with Lafora body disease exhibit sustained sensorimotor cortex
    hyperexcitability with prolonged facilitation, consistent with severe
    impairment of inhibitory mechanisms. Hippocampal synaptic plasticity is
    disrupted in malin-knockout mice and is rescued when glycogen synthesis
    is reduced. The resulting hyperexcitability underlies the action and
    stimulus-sensitive myoclonus, photosensitive seizures, occipital
    (visual-hallucinatory) seizures, and progression to refractory epilepsy
    that defines the clinical syndrome.
  cell_types:
  - preferred_term: Pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  - preferred_term: Interneuron
    term:
      id: CL:0000099
      label: interneuron
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Transmission of nerve impulse
    term:
      id: GO:0019226
      label: transmission of nerve impulse
  - preferred_term: Regulation of long-term neuronal synaptic plasticity
    term:
      id: GO:0048169
      label: regulation of long-term neuronal synaptic plasticity
  downstream:
  - target: Myoclonus
    description: >
      Sustained sensorimotor cortex hyperexcitability with impaired inhibition
      generates the action and stimulus-sensitive myoclonus that defines the
      progressive myoclonus epilepsy phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15623692
      reference_title: "Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The LBD findings highlight sustained hyperexcitability of the sensorimotor cortex in response to afferent stimuli, which fit with a more severe impairment of inhibitory mechanisms."
      explanation: Direct human electrophysiologic linkage of sustained sensorimotor cortex hyperexcitability to the action myoclonus phenotype.
  - target: Seizures
    description: >
      Cortical hyperexcitability and loss of inhibitory tone produce
      progressive epileptic seizures that become drug-resistant.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:24452334
      reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These animals did not show the increase in markers of neurodegeneration, the impairments in electrophysiological properties of hippocampal synapses, nor the susceptibility to kainate-induced epilepsy seen in the malin knockout model."
      explanation: Genetic rescue of glycogen synthesis abolishes synaptic dysfunction and seizure susceptibility, establishing the causal direction from synaptic dysfunction to epilepsy.
  - target: Generalized tonic-clonic seizures
    description: >
      Cortical hyperexcitability supports generalization to bilateral
      tonic-clonic seizures.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Soon thereafter myoclonus appears and a generalized tonic-clonic seizure."
      explanation: Generalized tonic-clonic seizures are part of the hyperexcitable epilepsy phenotype in Lafora disease.
  - target: Absence seizures
    description: >
      Aberrant cortico-thalamic synchronization yields atypical and
      myoclonic absence seizures that become near-continuous as the
      disease progresses.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Atypical and myoclonic absences set in and then become so constant that the young patient’s every thought and sentence are constantly interrupted and incomplete."
      explanation: Absence seizures are part of the progressive Lafora epilepsy phenotype downstream of network hyperexcitability.
  - target: Visual hallucinations
    description: >
      Occipital cortical hyperexcitability produces photosensitive epileptic
      visual hallucinations.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:11483392
      reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Characteristic seizures include myoclonic and occipital lobe seizures with visual hallucinations, scotomata, and photoconvulsions."
      explanation: Occipital-lobe seizures with visual hallucinations directly support this hyperexcitability edge.
  - target: Photosensitive seizures
    description: >
      Cortical hyperexcitability with impaired inhibition produces
      photoparoxysmal/photosensitive seizure responses.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29489177
      reference_title: "Lafora Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
      explanation: Photosensitive seizures are a characteristic Lafora epilepsy manifestation.
  - target: Status epilepticus
    description: >
      Loss of inhibitory control and progressive neurodegeneration culminate
      in episodes of status epilepticus, frequently lethal.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Most patients pass away in status epilepticus or from aspiration pneumonia secondary to neurological loss of the ability to control secretions."
      explanation: Status epilepticus is a frequent terminal manifestation of the progressive hyperexcitable epilepsy syndrome.
  - target: Atonic (drop) attacks
    description: >
      Cortical network hyperexcitability also manifests as atonic and drop
      attacks that drive loss of ambulation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Within a few years the patient is out of school and is unable to walk mainly because of frequent myoclonic and atonic attacks."
      explanation: Atonic attacks are a disabling seizure manifestation in the Lafora epilepsy phenotype.
  evidence:
  - reference: PMID:15623692
    reference_title: "Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The LBD findings highlight sustained hyperexcitability of the sensorimotor cortex in response to afferent stimuli, which fit with a more severe impairment of inhibitory mechanisms."
    explanation: Direct human electrophysiologic evidence that Lafora body disease features sustained cortical hyperexcitability with impaired inhibition.
  - reference: PMID:24452334
    reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These animals did not show the increase in markers of neurodegeneration, the impairments in electrophysiological properties of hippocampal synapses, nor the susceptibility to kainate-induced epilepsy seen in the malin knockout model."
    explanation: Genetic rescue of glycogen synthesis in malin-knockout mice restores hippocampal synaptic electrophysiology and abolishes kainate-induced seizure susceptibility, linking glycogen-driven synaptic dysfunction to epileptogenesis.
  - reference: PMID:39806098
    reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "polyglucosan bodies induce neuroinflammation"
    explanation: Polyglucosan-induced neuroinflammation is implicated in the network excitability changes that drive seizures.
- name: Neurodegeneration
  description: >
    Cumulative effects of Lafora body burden, neuroinflammation, oxidative
    stress, and autophagic impairment drive progressive neurodegeneration in
    cortex, hippocampus, and cerebellum. Cerebellar Purkinje cell involvement
    contributes to ataxia. Mouse models recapitulate this neurodegeneration,
    and genetic reduction of glycogen synthesis prevents it, identifying
    polyglucosan accumulation as the principal upstream driver. CHI3L1/YKL40
    has emerged as a candidate biomarker of neurodegeneration in LD models.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  biological_processes:
  - preferred_term: Neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
  downstream:
  - target: Progressive cognitive decline and dementia
    description: >
      Cortical and hippocampal neuron loss produces relentless cognitive
      deterioration ending in profound dementia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:11483392
      reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The course of the disease consists of worsening seizures and an inexorable decline in mental and other neurologic functions that result in dementia and death within 10 years of onset."
      explanation: Progressive neurologic decline in Lafora disease culminates in dementia.
  - target: Ataxia
    description: >
      Cerebellar neurodegeneration, including Purkinje cell involvement,
      contributes to ataxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29489177
      reference_title: "Lafora Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
      explanation: Ataxia is a characteristic neurologic manifestation of progressive Lafora disease.
  - target: Progressive neurologic deterioration
    description: >
      Cumulative cortical and subcortical neuron loss underlies the
      relentless progression to a vegetative state.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade."
      explanation: The clinical course documents relentless neurologic deterioration to end-stage disease.
  - target: Cerebral atrophy
    description: >
      Cortical neuronal loss yields cerebral atrophy on neuroimaging in
      later disease.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
      explanation: Lafora body-driven neurodegeneration provides the mechanistic basis for cerebral atrophy.
  - target: Cerebellar atrophy
    description: >
      Cerebellar neurodegeneration produces cerebellar atrophy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: PARTIAL
      evidence_source: MODEL_ORGANISM
      snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
      explanation: General Lafora body-driven neurodegeneration indirectly supports cerebellar atrophy as a regional manifestation.
  - target: Dysarthria
    description: >
      Cortical and cerebellar neurodegeneration disrupts motor speech
      coordination.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301563
      reference_title: "Progressive Myoclonus Epilepsy, Lafora Type."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Dysarthria and ataxia appear early, while spasticity appears late."
      explanation: Dysarthria is a neurologic manifestation occurring with ataxia in Lafora disease.
  - target: Apraxia
    description: >
      Cortical neurodegeneration produces apraxia.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29489177
      reference_title: "Lafora Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
      explanation: Apraxia is a characteristic manifestation of Lafora disease.
  - target: Cortical visual impairment
    description: >
      Occipital and association-cortex degeneration can progress from visual
      seizures and hallucinations to cortical visual loss.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29489177
      reference_title: "Lafora Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
      explanation: Cortical blindness is a characteristic late neurologic feature of Lafora disease.
  - target: Dysphagia
    description: >
      Advanced neurologic deterioration impairs swallowing and secretion
      control, increasing aspiration risk.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301563
      reference_title: "Progressive Myoclonus Epilepsy, Lafora Type."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Gastrostomy feedings can decrease the risk of aspiration pneumonia when the disease is advanced."
      explanation: Advanced disease requires gastrostomy to reduce aspiration risk, supporting dysphagia as a late neurologic consequence.
  - target: Vegetative state
    description: >
      End-stage cortical and subcortical neurodegeneration culminates in a
      vegetative state.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade."
      explanation: The clinical natural history directly documents progression to vegetative state.
  - target: Neuropsychiatric symptoms
    description: >
      Cortical dysfunction and progressive dementia produce behavioral and
      neuropsychiatric manifestations.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30336494
      reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Behavioral abnormalities emerge, commonly in the realm of a disinhibited dementia."
      explanation: Behavioral abnormalities are part of the progressive dementia phenotype.
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
    explanation: Establishes Lafora bodies as the principal upstream driver of neurodegeneration in genetic mouse models.
  - reference: PMID:24452334
    reference_title: "Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our findings reveal that glycogen accumulation accounts for the neurodegeneration and functional consequences seen in the malin knockout model, as well as the impaired autophagy."
    explanation: Genetic ablation of glycogen synthesis rescues neurodegeneration in malin knockout mice, establishing glycogen accumulation as proximal to neurodegeneration.
biochemical:
- name: Poorly branched hyperphosphorylated glycogen
  biomarker_term:
    preferred_term: glycogen
    term:
      id: CHEBI:28087
      label: glycogen
  presence: ABNORMAL
  context: >
    Lafora disease produces qualitatively abnormal glycogen with poor branching,
    overlong chains, hyperphosphorylation, and reduced solubility. Because
    polyglucosan and hyperphosphorylated glycogen do not have more specific
    local CHEBI terms, this readout is anchored to glycogen with abnormal
    context.
  readouts:
  - target: Aberrant glycogen chain length and hyperphosphorylation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Detecting poorly branched, hyperphosphorylated glycogen reports the
      abnormal glycogen-architecture node upstream of Lafora body formation.
    evidence:
    - reference: PMID:30143794
      reference_title: "Lafora disease - from pathogenesis to treatment strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
      explanation: >
        The abnormal glycogen species directly corresponds to the upstream
        glycogen-architecture mechanism.
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The absence of either protein results in poorly branched, hyperphosphorylated glycogen, which precipitates, aggregates and accumulates into Lafora bodies."
    explanation: >
      This review links loss of laforin or malin to abnormal poorly branched,
      hyperphosphorylated glycogen.
- name: Polyglucosan chain length abnormality
  biomarker_term:
    preferred_term: glycogen
    term:
      id: CHEBI:28087
      label: glycogen
  presence: ABNORMAL
  context: >
    Polyglucosans in Lafora disease are glycogen molecules with overlong
    glucan chains. This readout separates abnormal chain length from total
    glycogen amount because chain length is the key determinant of
    insolubility in newer mechanistic studies.
  readouts:
  - target: Aberrant glycogen chain length and hyperphosphorylation
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Overlong glycogen chains report the abnormal-chain-length component of
      the Lafora glycogen lesion.
    evidence:
    - reference: PMID:39806098
      reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."
      explanation: >
        The paper defines Lafora polyglucosans by overlong glycogen chains,
        supporting chain-length abnormality as a mechanistic readout.
  evidence:
  - reference: PMID:39806098
    reference_title: "Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Polyglucosans are glycogen molecules with overlong chains, which are hyperphosphorylated in the neurodegenerative Lafora disease (LD)."
    explanation: >
      Defines the polyglucosan storage material as abnormal glycogen with
      overlong chains and hyperphosphorylation.
- name: Lafora body glycogen storage burden
  biomarker_term:
    preferred_term: glycogen
    term:
      id: CHEBI:28087
      label: glycogen
  presence: INCREASED
  context: >
    Lafora bodies are insoluble, glycogen-like polyglucosan inclusions in
    neurons, astrocytes, skin sweat gland duct cells, and other tissues. Their
    presence is a diagnostic tissue readout of the disease storage lesion.
  readouts:
  - target: Lafora body accumulation in neurons and astrocytes
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: >
      Increased Lafora body glycogen burden reports the intracellular storage
      node that drives downstream neuroinflammation and neurodegeneration.
    evidence:
    - reference: PMID:29489177
      reference_title: "Lafora Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The presence of the pathognomic Lafora bodies in a tissue biopsy is diagnostic of Lafora disease."
      explanation: >
        Diagnostic tissue detection of Lafora bodies supports this storage
        burden as a positive readout of the Lafora body accumulation node.
  evidence:
  - reference: PMID:29483193
    reference_title: "Lafora disease offers a unique window into neuronal glycogen metabolism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Individuals with LD develop cytoplasmic, aberrant glycogen inclusions in nearly all tissues that more closely resemble plant starch than human glycogen."
    explanation: >
      Human Lafora disease is characterized by cytoplasmic aberrant glycogen
      inclusions in many tissues.
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of the pathognomic Lafora bodies in a tissue biopsy is diagnostic of Lafora disease."
    explanation: >
      Tissue biopsy evidence supports Lafora bodies as the diagnostic storage
      readout.
- name: Brain glycogen accumulation
  biomarker_term:
    preferred_term: glycogen
    term:
      id: CHEBI:28087
      label: glycogen
  presence: INCREASED
  context: >
    Experimental Lafora disease models quantify brain glycogen accumulation
    and insoluble glycogen-like Lafora bodies to monitor disease state and
    response to GYS1-lowering interventions.
  readouts:
  - target: PTG/glycogen synthase overactivation and excessive glycogen synthesis
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >
      Increased brain glycogen reports excessive GYS1-driven glycogen
      synthesis and the storage burden produced by the overactive
      glycogen-synthesis node.
    evidence:
    - reference: PMID:33277363
      reference_title: "An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."
      explanation: >
        Mouse-model evidence identifies glycogen accumulation and insoluble
        Lafora bodies as hallmark readouts of the synthesis-driven storage
        process.
  - target: Lafora body accumulation in neurons and astrocytes
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: MONITORING
    interpretation: >
      Brain glycogen accumulation tracks the storage burden that accumulates
      as insoluble Lafora bodies.
    evidence:
    - reference: PMID:33277363
      reference_title: "An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."
      explanation: >
        Mouse-model evidence pairs glycogen accumulation with Lafora body
        formation as linked storage-burden readouts.
  evidence:
  - reference: PMID:33277363
    reference_title: "An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Hallmarks of LD are glycogen accumulation and formation of LBs, which are insoluble, glycogen-like particles, characterized by reduced branching and long chains (25)."
    explanation: >
      Defines glycogen accumulation and Lafora body formation as hallmark
      biochemical findings in Lafora disease models.
phenotypes:
- category: Neurological
  name: Myoclonus
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: >
    Action myoclonus and stimulus-sensitive myoclonus are prominent features,
    typically progressing from mild to intractable.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
    explanation: Confirms myoclonus as a characteristic and intractable feature of Lafora disease.
- category: Neurological
  name: Seizures
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: >
    Multiple seizure types including generalized tonic-clonic, myoclonic,
    absence, and visual (occipital) seizures. Seizures become increasingly
    refractory to treatment.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:20527995
    reference_title: "Lafora disease: epidemiology, pathophysiology and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The condition is characterized by epilepsy, myoclonus and dementia."
    explanation: Confirms seizures as one of the three cardinal features of Lafora disease.
- category: Neurological
  name: Generalized tonic-clonic seizures
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Soon thereafter myoclonus appears and a generalized tonic-clonic seizure."
    explanation: Confirms generalized tonic-clonic seizures as a presenting feature.
- category: Neurological
  name: Absence seizures
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Absence seizure
    term:
      id: HP:0002121
      label: Generalized non-motor (absence) seizure
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Atypical and myoclonic absences set in and then become so constant that the young patient’s every thought and sentence are constantly interrupted and incomplete."
    explanation: Describes the progression of absence seizures becoming constant and severely disabling.
- category: Neurological
  name: Visual hallucinations
  frequency: FREQUENT
  diagnostic: true
  notes: >
    Occipital seizures with visual hallucinations are a characteristic early feature
    and may precede other seizure types.
  phenotype_term:
    preferred_term: Visual hallucination
    term:
      id: HP:0002367
      label: Visual hallucination
  evidence:
  - reference: PMID:11483392
    reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic seizures include myoclonic and occipital lobe seizures with visual hallucinations, scotomata, and photoconvulsions."
    explanation: Confirms visual hallucinations from occipital seizures as a characteristic feature.
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient commonly develops visual hallucinations, usually frightening which have been shown to be both epileptic and psychotic."
    explanation: Confirms visual hallucinations as a common feature with both epileptic and psychotic components.
- category: Neurological
  name: Progressive cognitive decline and dementia
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: >
    Relentless cognitive deterioration beginning within a few years of seizure onset,
    progressing to severe dementia. Cognitive decline typically becomes apparent
    2-5 years after seizure onset.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: PMID:11483392
    reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The course of the disease consists of worsening seizures and an inexorable decline in mental and other neurologic functions that result in dementia and death within 10 years of onset."
    explanation: Confirms progressive cognitive decline leading to dementia as a cardinal feature with a 10-year disease course.
  - reference: PMID:36899857
    reference_title: "Role of Astrocytes in the Pathophysiology of Lafora Disease and Other Glycogen Storage Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the disease progresses rapidly with dementia, neuropsychiatric symptoms, and cognitive deterioration and has a fatal outcome within 5-10 years after onset."
    explanation: Confirms rapid progression to dementia with fatal outcome within 5-10 years.
- category: Neurological
  name: Progressive neurologic deterioration
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Progressive neurologic deterioration
    term:
      id: HP:0002344
      label: Progressive neurologic deterioration
  notes: >
    Progressive neurological deterioration encompasses dysarthria, cerebellar ataxia,
    and cerebral atrophy visible on neuroimaging in later disease stages. These features
    develop as the disease advances toward a vegetative state.
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade."
    explanation: Describes the progressive neurological deterioration culminating in a vegetative state.
- category: Neurological
  name: Ataxia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
    explanation: Confirms ataxia as a characteristic feature of Lafora disease.
- category: Neurological
  name: Photosensitive seizures
  frequency: FREQUENT
  notes: >
    Photoparoxysmal/photosensitive responses are characteristic on EEG and
    photoconvulsive seizures are commonly elicited.
  phenotype_term:
    preferred_term: Photosensitive myoclonic seizure
    term:
      id: HP:0001327
      label: Photosensitive myoclonic seizure
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
    explanation: Confirms photosensitive seizures as a characteristic feature.
  - reference: PMID:11483392
    reference_title: "Lafora's disease: towards a clinical, pathologic, and molecular synthesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic seizures include myoclonic and occipital lobe seizures with visual hallucinations, scotomata, and photoconvulsions."
    explanation: Describes photoconvulsions as part of the characteristic occipital seizure phenotype.
- category: Neurological
  name: Status epilepticus
  frequency: FREQUENT
  notes: >
    Episodes of status epilepticus mark advanced disease, often follow
    dramatic loss of awareness, and are a common terminal event.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most patients pass away in status epilepticus or from aspiration pneumonia secondary to neurological loss of the ability to control secretions."
    explanation: Documents status epilepticus as a frequent terminal event in Lafora disease.
- category: Neurological
  name: Atonic (drop) attacks
  frequency: FREQUENT
  notes: >
    Atonic and myoclonic-atonic attacks contribute substantially to loss of
    ambulation; affected patients are often unable to walk within a few years
    of onset because of frequent drop attacks.
  phenotype_term:
    preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Within a few years the patient is out of school and is unable to walk mainly because of frequent myoclonic and atonic attacks."
    explanation: Documents the loss of ambulation due to myoclonic and atonic attacks.
- category: Neurological
  name: Apraxia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Apraxia
    term:
      id: HP:0002186
      label: Apraxia
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
    explanation: Confirms apraxia as a characteristic feature of Lafora disease.
- category: Neurological
  name: Cortical visual impairment
  frequency: OCCASIONAL
  notes: >
    Cortical blindness from advanced occipital and association cortex
    involvement; visual phenomena (hallucinations, scotomata) typically
    precede frank cortical visual loss.
  phenotype_term:
    preferred_term: Cortical blindness
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
    explanation: Confirms cortical blindness as a characteristic late feature of Lafora disease.
- category: Neurological
  name: Cerebral atrophy
  frequency: FREQUENT
  notes: >
    Generalized cortical atrophy is seen on neuroimaging in advancing
    disease, reflecting cumulative cortical neurodegeneration.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
    explanation: Supports the neurodegenerative basis of cerebral atrophy seen in advancing disease.
- category: Neurological
  name: Cerebellar atrophy
  frequency: OCCASIONAL
  notes: >
    Cerebellar atrophy reflects Purkinje cell and cerebellar cortical
    neurodegeneration, contributing to ataxia and dysarthria in advancing
    disease.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
    explanation: Indirect support; cerebellar atrophy is part of widespread Lafora-body-driven neurodegeneration.
- category: Neurological
  name: Dysarthria
  frequency: FREQUENT
  notes: >
    Progressive dysarthria emerges in mid-to-late disease, reflecting
    combined cerebellar and cortical motor neurodegeneration.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:20301563
    reference_title: "Progressive Myoclonus Epilepsy, Lafora Type."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dysarthria and ataxia appear early, while spasticity appears late."
    explanation: GeneReviews entry for Lafora disease explicitly lists dysarthria as an early feature alongside ataxia.
- category: Neurological
  name: Dysphagia
  frequency: FREQUENT
  notes: >
    Progressive bulbar dysfunction leads to dysphagia and aspiration risk in
    advanced disease. Gastrostomy feeding is recommended to reduce aspiration
    pneumonia, a common cause of death in late-stage Lafora disease.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:20301563
    reference_title: "Progressive Myoclonus Epilepsy, Lafora Type."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gastrostomy feedings can decrease the risk of aspiration pneumonia when the disease is advanced."
    explanation: GeneReviews recommends gastrostomy in advanced disease to address dysphagia-related aspiration pneumonia risk.
- category: Neurological
  name: Vegetative state
  frequency: VERY_FREQUENT
  notes: >
    End-stage Lafora disease progresses to a vegetative state with little
    or no responsiveness; if airways are maintained patients can survive
    into early adulthood despite extensive Lafora body burden.
  phenotype_term:
    preferred_term: Vegetative state
    term:
      id: HP:0031358
      label: Vegetative state
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients undergo first insidious then rapid progressive myoclonus epilepsy toward a vegetative state and death within a decade."
    explanation: Documents progression to a vegetative state as the natural end-stage of disease.
- category: Behavioral
  name: Neuropsychiatric symptoms
  frequency: FREQUENT
  notes: >
    Behavioral abnormalities and neuropsychiatric symptoms (including
    disinhibited dementia, depression, and anxiety) emerge as Lafora disease
    progresses.
  phenotype_term:
    preferred_term: Behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Characteristic features of Lafora disease include intractable myoclonic and photosensitive seizures, drop attacks, ataxia, apraxia, cortical blindness, rapidly progressive dementia, and neuropsychiatric symptoms."
    explanation: Confirms neuropsychiatric symptoms as a characteristic feature of Lafora disease.
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Behavioral abnormalities emerge, commonly in the realm of a disinhibited dementia."
    explanation: Documents disinhibited dementia as the typical neuropsychiatric phenotype.
diagnosis:
- name: Skin biopsy for Lafora bodies
  description: >
    Axillary skin biopsy demonstrating periodic acid-Schiff (PAS)-positive
    Lafora bodies in apocrine sweat gland duct cells is a classical diagnostic
    method, though it has limited sensitivity.
  presence: PAS-positive polyglucosan inclusions in eccrine/apocrine sweat gland duct cells.
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of the pathognomic Lafora bodies in a tissue biopsy is diagnostic of Lafora disease."
    explanation: Confirms Lafora bodies in tissue biopsy as pathognomonic for diagnosis.
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "LB are found in skin eccrine sweat gland ducts. They are also found in the myoepithelia of apocrine glands"
    explanation: Specifies the skin locations where Lafora bodies can be found on biopsy.
- name: Genetic testing
  description: >
    Molecular genetic testing for EPM2A and NHLRC1 is the gold standard for
    confirmatory diagnosis. Sequencing and deletion/duplication analysis of
    both genes identifies biallelic pathogenic variants in the majority of cases.
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Today, the diagnosis of LD is based on biallelic mutation identification in either the EPM2A or EPM2B gene."
    explanation: Confirms genetic testing as the current diagnostic standard.
- name: EEG findings
  description: >
    Electroencephalography shows background slowing with generalized spike-wave
    and polyspike-wave discharges, often with occipital predominance and
    photosensitivity. Progressive deterioration of EEG background over the
    disease course.
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "successive electroencephalographs (EEG’s) show, unlike in JME, a slowing background and spike-wave discharges"
    explanation: Describes the characteristic EEG findings distinguishing Lafora disease from JME.
genetic:
- name: EPM2A
  association: Causative
  notes: >
    Encodes laforin, a dual-specificity glycogen phosphatase. Biallelic
    loss-of-function variants (missense, nonsense, frameshift, splice-site,
    deletions) cause approximately 44% of cases in a 2023 patient-level
    meta-analysis (109/250 cases; 67 distinct variants reported). PT/PT
    genotype most common (~53%).
  gene_term:
    preferred_term: EPM2A
    term:
      id: hgnc:3413
      label: EPM2A
  evidence:
  - reference: PMID:37658439
    reference_title: "Prognostic value of pathogenic variants in Lafora disease: systematic review and meta-analysis of patient-level data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mutated gene was NHLRC1 in 56% and EPM2A in 44% of cases. 114 pathogenic variants (67 EPM2A; 47 NHLRC1) were identified."
    explanation: Patient-level meta-analysis quantifying the relative contribution of EPM2A vs NHLRC1 in Lafora disease.
  - reference: CGGV:assertion_f970ced6-0164-41ed-9e1f-1fb9f892bca6-2020-05-23T190000.000Z
    reference_title: "EPM2A / Lafora disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "EPM2A | HGNC:3413 | Lafora disease | MONDO:0009697 | AR | Definitive"
    explanation: ClinGen classifies the EPM2A-Lafora disease gene-disease relationship as definitive with autosomal recessive inheritance.
- name: NHLRC1
  association: Causative
  notes: >
    Encodes malin, an E3 ubiquitin ligase. Biallelic loss-of-function variants
    cause approximately 56% of cases (141/250; 47 distinct variants). MS/MS
    genotype most common (~53%). Critical prognostic genotype: biallelic
    protein-truncating (PT/PT) variants are associated with shorter survival
    (HR 2.88; 95% CI 1.23-6.78) and a trend toward earlier loss of autonomy.
    Homozygous p.Asp146Asn confers a more favorable course.
  gene_term:
    preferred_term: NHLRC1
    term:
      id: hgnc:21576
      label: NHLRC1
  evidence:
  - reference: PMID:37658439
    reference_title: "Prognostic value of pathogenic variants in Lafora disease: systematic review and meta-analysis of patient-level data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study demonstrates the existence of prognostic genetic factors in LD, namely the genotype defined according to the functional impact of the pathogenic variants."
    explanation: Establishes that the functional impact of NHLRC1/EPM2A variants is prognostically informative in Lafora disease.
  - reference: PMID:37658439
    reference_title: "Prognostic value of pathogenic variants in Lafora disease: systematic review and meta-analysis of patient-level data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The population carrying the homozygous p.Asp146Asn variant of NHLRC1 genotype was confirmed to have a more favourable prognosis in terms of disease duration."
    explanation: Identifies homozygous NHLRC1 p.Asp146Asn as a favorable-prognosis genotype.
  - reference: PMID:37658439
    reference_title: "Prognostic value of pathogenic variants in Lafora disease: systematic review and meta-analysis of patient-level data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it may be speculated that malin plays a pivotal role in LD pathogenesis."
    explanation: Authors interpret the worse prognosis with truncating NHLRC1 variants as evidence for malin's pivotal pathogenic role.
  - reference: CGGV:assertion_c4dbe715-b897-482d-afeb-b05c0653a79a-2020-03-03T170000.000Z
    reference_title: "NHLRC1 / Lafora disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NHLRC1 | HGNC:21576 | Lafora disease | MONDO:0009697 | AR | Definitive"
    explanation: ClinGen classifies the NHLRC1-Lafora disease gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Antiseizure medications
  description: >
    Valproic acid, clonazepam, levetiracetam, perampanel, and zonisamide are
    used for seizure management but become progressively less effective as the
    disease advances. Sodium channel blockers (carbamazepine, phenytoin) may
    exacerbate myoclonus and should be avoided.
  treatment_term:
    preferred_term: Anticonvulsant agent therapy
    term:
      id: MAXO:0000167
      label: anticonvulsant agent therapy
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sodium channel blocking antiseizure medications, such as phenytoin worsen myoclonus and probably seizures but can be very beneficial in stopping status epilepticus."
    explanation: Documents that sodium channel blockers worsen myoclonus while being useful for status epilepticus.
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Antiepileptic drugs can be used for the management of myoclonus and seizures. However, patients can become drug-resistant over time, resulting in disease progression, increased seizure frequency, and a decline in neurologic function."
    explanation: Confirms progressive drug resistance as a hallmark of the disease course.
- name: Metformin
  description: >
    Metformin has been studied as a potential disease-modifying adjunct in Lafora
    disease, with model-organism data and an 18-patient observational follow-up
    suggesting slower clinical progression in treated patients.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: metformin
      term:
        id: CHEBI:6801
        label: metformin
  target_mechanisms:
  - target: Aberrant glycogen chain length and hyperphosphorylation
    treatment_effect: MODULATES
    description: >
      Metformin treatment reduced Lafora body formation and neurological
      abnormalities in Lafora disease mouse models and was associated with
      slower progression in treated patients, plausibly by reducing glycogen
      accumulation upstream of polyglucosan formation.
  evidence:
  - reference: PMID:36303102
    reference_title: "Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, we conducted a follow-up study of an initial cohort of 18 patients with Lafora disease, 8 treated with metformin and 10 untreated."
    explanation: Documents the human Lafora disease cohort used to compare metformin-treated and untreated patients.
  - reference: PMID:36303102
    reference_title: "Early Treatment with Metformin Improves Neurological Outcomes in Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover, patients receiving metformin had a slower progression of the disease."
    explanation: Supports slower clinical progression in metformin-treated patients in the human follow-up cohort.
- name: Supportive and palliative care
  description: >
    As the disease progresses, management becomes primarily supportive and palliative,
    including nutritional support, physiotherapy, and management of complications
    such as aspiration pneumonia.
  treatment_term:
    preferred_term: Supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:29489177
    reference_title: "Lafora Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management Lafora disease focuses on symptomatic relief of seizures and myoclonus, together with palliative, supportive, and rehabilitative measures."
    explanation: Confirms palliative and supportive care as the mainstay of management.
- name: Genetic counseling
  description: >
    Genetic counseling is recommended for affected families to inform about
    recurrence risk (25% for each pregnancy when both parents are carriers),
    carrier testing, and prenatal diagnosis options. Counseling should now
    incorporate genotype-based prognostic information: biallelic
    protein-truncating variants in NHLRC1 are associated with worse survival
    (HR 2.88; 95% CI 1.23-6.78), while homozygous NHLRC1 p.Asp146Asn carries
    a more favorable prognosis.
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lafora disease is a severe, autosomal recessive, progressive myoclonus epilepsy."
    explanation: Establishes the autosomal recessive inheritance pattern that drives the 25% per-pregnancy recurrence risk and motivates genetic counseling for carrier couples.
  - reference: PMID:37658439
    reference_title: "Prognostic value of pathogenic variants in Lafora disease: systematic review and meta-analysis of patient-level data."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study demonstrates the existence of prognostic genetic factors in LD, namely the genotype defined according to the functional impact of the pathogenic variants."
    explanation: Justifies adding genotype-based prognostic counseling alongside standard recurrence-risk counseling.
- name: Glycogen synthase 1 (GYS1) antisense oligonucleotide therapy (experimental)
  description: >
    Substrate reduction therapy using antisense oligonucleotides targeting
    GYS1 mRNA to lower brain glycogen synthesis and prevent Lafora body
    formation. Preclinical Gys1-ASO administration in Epm2b-/- mice reduced
    GYS1 protein, glycogen aggregation, Lafora body burden, and epileptiform
    discharges. ION283 (intrathecal ASO) is now in a Phase 1/2 clinical trial
    in patients aged 10-18 with genetically confirmed EPM2A or NHLRC1 disease
    (NCT06609889). This represents the first disease-modifying strategy
    advanced to clinical trials in Lafora disease.
  treatment_term:
    preferred_term: antisense oligonucleotide therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: PTG/glycogen synthase overactivation and excessive glycogen synthesis
    treatment_effect: INHIBITS
    description: >
      ASO-mediated reduction of GYS1 expression directly addresses the
      overactive glycogen synthesis node, halting polyglucosan/Lafora body
      accumulation in mouse models.
    evidence:
    - reference: PMID:37700152
      reference_title: "Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a Lafora disease mouse model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "an antisense oligonucleotide (ASO) was developed to reduce glycogen synthesis in the brain by targeting glycogen synthase 1 (Gys1)."
      explanation: Establishes that the ASO mechanism is direct knockdown of GYS1, the overactive glycogen synthase node in the pathograph.
  evidence:
  - reference: PMID:37700152
    reference_title: "Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a Lafora disease mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The mice treated with Gys1-ASO exhibited decreased Gys1 protein levels, decreased glycogen aggregation, and reduced epileptiform discharges compared to untreated Epm2b-/- mice."
    explanation: Preclinical demonstration that Gys1-ASO reduces glycogen aggregation and epileptiform discharges in malin-deficient mice.
  - reference: PMID:37700152
    reference_title: "Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a Lafora disease mouse model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This work provides proof of concept that a Gys1-ASO halts disease progression of EPM2B mutations of Lafora disease."
    explanation: Establishes proof of concept that GYS1-ASO halts disease progression, supporting the rationale for ION283 clinical translation.
- name: Perampanel
  description: >
    Perampanel, a non-competitive AMPA receptor antagonist, has shown
    benefit on cortical action myoclonus and disability in case series of
    progressive myoclonic epilepsies including Lafora disease. It is one
    of the few add-on antiseizure medications with clinically observable
    benefit on the action myoclonus that defines disability in PMEs.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: perampanel
      term:
        id: CHEBI:71013
        label: perampanel
  evidence:
  - reference: PMID:33841303
    reference_title: "Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we are reporting the effectiveness of perampanel in five individuals affected by Unverricht-Lundborg disease, three by Lafora disease, two by sialidosis, and one by an undetermined PME."
    explanation: Reports case-series effectiveness of perampanel in Lafora disease patients.
- name: Ketogenic diet (experimental)
  description: >
    A restricted-carbohydrate ketogenic diet has been historically explored
    in advanced Lafora disease (NCT00007124). The hypothesis is that
    restricting carbohydrate substrate reduces brain glycogen synthesis and
    polyglucosan accumulation. The completed trial did not establish disease
    modification in advanced cases; the strategy remains of theoretical
    interest in newly diagnosed patients.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:30336494
    reference_title: "Lafora Disease: A Review of Molecular Mechanisms and Pathology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ketogenic diet has been tried but without success, albeit in relatively advanced cases."
    explanation: Documents the historical trial of ketogenic diet without disease-modifying success in advanced Lafora disease.
clinical_trials:
- name: NCT06609889
  phase: PHASE_I
  status: RECRUITING
  description: >
    A Phase 1/2 open-label study to evaluate the safety and efficacy of
    intrathecally administered ION283 (an antisense oligonucleotide targeting
    glycogen synthesis) in patients aged 10-18 years with genetically
    confirmed EPM2A or EPM2B/NHLRC1 Lafora disease. EEG biomarkers (background
    rhythms, sleep physiology, electrographic seizures, and epileptiform
    discharge counts) are used as efficacy endpoints over 2 years.
  target_phenotypes:
  - preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT06609889
    reference_title: "A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease"
    supports: SUPPORT
    snippet: "This study will test the safety and efficacy of multiple doses of ION283 administered as intrathecal (IT) injections by lumbar puncture (LP)."
    explanation: First-in-human disease-modifying trial in Lafora disease using intrathecal ASO targeting glycogen synthesis.
- name: NCT03876522
  status: COMPLETED
  description: >
    Prospective, longitudinal, observational study of the natural history
    and functional status of patients with Lafora disease. Sponsored by
    Ionis Pharmaceuticals to define disease course, identify biomarkers,
    and establish outcome measures (Lafora Disease Performance Scale,
    seizure frequency, EEG, cognition, gait/ataxia, caregiver burden,
    blood/CSF biomarkers) for use in future treatment trials.
  evidence:
  - reference: clinicaltrials:NCT03876522
    reference_title: "Prospective, Longitudinal, Observational Study of the Natural History and Functional Status of Patients With Lafora Disease"
    supports: SUPPORT
    snippet: "A natural history and functional status study to characterize the clinical disease course in Lafora disease patients using standardized, quantitative evaluations and to identify useful biomarkers and clinical outcome measures for use in future Lafora treatment studies."
    explanation: Defines outcome measures and biomarkers for the field, supporting design of subsequent disease-modifying trials.
- name: NCT00007124
  status: COMPLETED
  description: >
    Trial of a ketogenic diet in advanced Lafora disease, sponsored by
    NINDS. Tested whether a restricted-carbohydrate ketogenic diet could
    modify disease course in patients aged 10 years and older with
    histologically or genetically confirmed Lafora disease. Did not yield
    disease modification in advanced cases.
  evidence:
  - reference: clinicaltrials:NCT00007124
    reference_title: "A Trial of Ketogenic Diet in Lafora Disease"
    supports: SUPPORT
    snippet: "This study will examine the effect of a restricted-carbohydrate diet (ketogenic diet) on Lafora disease-a severe neurological disease in which brain cells die because of abnormal accumulation of glucose (a type of sugar)."
    explanation: NIH-sponsored trial of ketogenic diet in advanced Lafora disease.
animal_models:
- species: Mouse
  genotype: Epm2a-/-
  description: >
    Laforin knockout mice develop Lafora bodies in brain and other tissues,
    along with progressive myoclonus epilepsy, neurodegeneration, and behavioral
    abnormalities recapitulating key features of human Lafora disease.
  genes:
  - preferred_term: EPM2A
    term:
      id: hgnc:3413
      label: EPM2A
  evidence:
  - reference: PMID:30143794
    reference_title: "Lafora disease - from pathogenesis to treatment strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Evidence from Lafora disease genetic mouse models indicates that these intracellular inclusions are a principal driver of neurodegeneration and neurological disease."
    explanation: Confirms Lafora disease mouse models recapitulate the neurodegeneration driven by Lafora body inclusions.
- species: Mouse
  genotype: Nhlrc1-/-
  description: >
    Malin knockout mice develop Lafora bodies and exhibit seizure susceptibility,
    neuroinflammation, and impaired autophagy similar to the human disease.
    They also show age-progressive reactive glia-derived neuroinflammation
    dominated by TNF and IL-6/JAK2 signaling and infiltration of peripheral
    T-lymphocytes into brain parenchyma, both ameliorated by fingolimod.
  genes:
  - preferred_term: NHLRC1
    term:
      id: hgnc:21576
      label: NHLRC1
  evidence:
  - reference: PMID:20538597
    reference_title: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Disruption of the Epm2b gene in mice resulted in viable animals that, by 3 months of age, accumulated Lafora bodies in the brain and to a lesser extent in heart and skeletal muscle."
    explanation: Confirms the malin knockout mouse model develops Lafora bodies recapitulating the human disease.
  - reference: PMID:36526090
    reference_title: "TNF and IL6/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we describe the infiltration of peripheral immune cells in the brain parenchyma, which could aggravate glia-derived neuroinflammation."
    explanation: Documents peripheral T-lymphocyte infiltration in the Epm2b-/- (NHLRC1) mouse model.
- species: Mouse
  genotype: Epm2a-/- with neuromuscular junction phenotyping
  description: >
    Re-phenotyping of laforin-deficient mice has revealed peripheral
    neuromuscular involvement: structural and functional impairment at the
    neuromuscular junction, reduced motor endplate area, fragmented junctions,
    loss of fully innervated junctions, alpha-motor neuron loss in lumbar
    spinal cord, and disorganized myofibrillar patterns with mild muscle
    atrophy. Provides a model for studying motor decline in Lafora disease
    beyond CNS pathology.
  genes:
  - preferred_term: EPM2A
    term:
      id: hgnc:3413
      label: EPM2A
  evidence:
  - reference: PMID:39301689
    reference_title: "Neuromuscular junction dysfunction in Lafora disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we found impairment in NMJ transmission, which coincided with altered expression of NMJ-associated genes and reduced motor endplate area, fragmented junctions and loss of fully innervated junctions at the NMJ."
    explanation: Establishes neuromuscular junction dysfunction as a peripheral phenotype in Epm2a-/- mice.

📚

References & Deep Research

References

1

PMID:20301563

Progressive Myoclonus Epilepsy, Lafora Type.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 43 citations 2026-04-25T18:53:35.673036

1. Disease Information

1.1 Definition and current understanding

LD is described in recent literature as a “rare, autosomal recessive neurodegenerative disorder” and a “progressive myoclonus epilepsy” with disrupted glycogen metabolism and “pathognomonic… Lafora bodies.” (aggradi2023laforadiseasea pages 1-2)

Abstract-supported definition quotes (recent): - “Lafora disease is a rare genetic disorder characterized by a disruption in glycogen metabolism. It manifests as progressive myoclonus epilepsy and cognitive decline during adolescence.” (Dec 2023; Brain Sciences) (aggradi2023laforadiseasea pages 1-2) - “Background Lafora disease (LD) is a fatal form of progressive myoclonic epilepsy caused by biallelic pathogenic variants in EPM2A or NHLRC1.” (Sep 2023; Orphanet J Rare Dis) (pondrelli2023prognosticvalueof pages 1-2)

1.2 Key identifiers, synonyms, and data provenance

The retrieved evidence directly supports MONDO and OMIM identifiers; other identifier systems (Orphanet/MeSH/ICD) were not captured in the retrieved sources.

Identifier system	ID/code	Preferred name	Synonyms/notes	URL
MONDO	MONDO:0009697	Lafora disease	Open Targets disease record for Lafora disease; Mendelian progressive myoclonus epilepsy entity (zimmern2024progressivemyoclonusepilepsy pages 6-7)	https://platform.opentargets.org/disease/MONDO_0009697
OMIM	OMIM #254780	Lafora disease	Also described as a rare autosomal recessive progressive myoclonic epilepsy; OMIM number explicitly stated in recent reviews/case report (aggradi2023laforadiseasea pages 1-2, rubio2024beneficialeffectof pages 1-2)	https://omim.org/entry/254780
Orphanet	Not captured in retrieved sources	Lafora disease	Not captured in retrieved sources; do not infer without direct evidence (aggradi2023laforadiseasea pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7)	Not captured in retrieved sources
MeSH	Not captured in retrieved sources	Lafora disease	Not captured in retrieved sources; progressive myoclonus epilepsy context noted in reviews, but no MeSH ID retrieved (aggradi2023laforadiseasea pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7)	Not captured in retrieved sources
ICD	Not captured in retrieved sources	Lafora disease	Not captured in retrieved sources; no ICD-10/ICD-11 code directly retrieved in available evidence (aggradi2023laforadiseasea pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7)	Not captured in retrieved sources

Table: This table summarizes key disease identifiers and naming information for Lafora disease using only retrieved evidence. It highlights confirmed MONDO and OMIM identifiers and clearly marks systems not directly captured in the available sources.

Common synonyms/alternative names (supported in retrieved sources): - “Lafora disease” and “progressive myoclonus epilepsy” (PME) framing (aggradi2023laforadiseasea pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7) - Genetic subtypes: “myoclonic epilepsy of Lafora 1/2” appear as MONDO entities in Open Targets (MONDO_0958199; MONDO_0800306), reflecting EPM2A vs NHLRC1 subtypes (Open Targets output embedded in evidence stream; disease MONDO confirmed) (aggradi2023laforadiseasea pages 1-2)

Evidence type note: This report primarily uses aggregated disease-level resources (systematic review/meta-analysis; scoping review; ClinicalTrials.gov records) plus patient-level case report evidence and multiple model organism studies. (pondrelli2023prognosticvalueof pages 1-2, aggradi2023laforadiseasea pages 1-2, NCT03876522 chunk 1)

2. Etiology

2.1 Disease causal factors

LD is a Mendelian disorder caused by loss-of-function biallelic pathogenic variants in: - EPM2A → laforin (glucan phosphatase/dual-specificity phosphatase) (pondrelli2023prognosticvalueof pages 1-2, donohue2023gys1antisensetherapy pages 1-2) - NHLRC1 (EPM2B) → malin (E3 ubiquitin ligase) (pondrelli2023prognosticvalueof pages 1-2, donohue2023gys1antisensetherapy pages 1-2)

Mechanistic genetic etiology: laforin and malin regulate glycogen metabolism and prevent conversion of soluble glycogen into insoluble polyglucosan aggregates (Lafora bodies). (pondrelli2023prognosticvalueof pages 1-2, duran2023roleofastrocytes pages 2-4)

2.2 Genetic risk factors (causal variants)

A 2023 systematic review/meta-analysis (patient-level) compiled 250 genetically confirmed cases and characterized variant classes and prognostic correlations. (pondrelli2023prognosticvalueof pages 1-2)

Gene (HGNC symbol)	Protein	Alternate gene name(s)	Inheritance	Typical variant types	Variant counts/statistics (Pondrelli 2023 meta-analysis)	Genotype–phenotype notes	Key citations
EPM2A	Laforin; glucan phosphatase; dual-specificity phosphatase	EPM2; myoclonic epilepsy of Lafora type 1	Autosomal recessive; disease caused by biallelic pathogenic variants	Missense/in-frame (MS); protein-truncating (PT) including nonsense, frameshift, splice-site, deletions; also point mutations and large deletions reported	67 distinct EPM2A variants among 250 genetically confirmed cases; 109/250 cases (43.6%) carried EPM2A variants; PT/PT genotype most common in EPM2A (53.2%) (pondrelli2023prognosticvalueof pages 2-4, pondrelli2023prognosticvalueof pages 1-2)	Causes classic Lafora disease via loss of laforin function and dysregulated glycogen metabolism; no specific survival HR for EPM2A genotype was highlighted in retrieved evidence, and some studies reported conflicting genotype–survival associations overall (zimmern2024progressivemyoclonusepilepsy pages 6-7, pondrelli2023prognosticvalueof pages 1-2)	DOI:10.1186/s13023-023-02880-6; https://doi.org/10.1186/s13023-023-02880-6 (pondrelli2023prognosticvalueof pages 1-2, pondrelli2023prognosticvalueof pages 2-4)
NHLRC1	Malin; E3 ubiquitin ligase	EPM2B; myoclonic epilepsy of Lafora type 2	Autosomal recessive; disease caused by biallelic pathogenic variants	Missense/in-frame (MS); protein-truncating (PT) including nonsense, frameshift, splice-site, deletions; intronless gene; point mutations also reported	47 distinct NHLRC1 variants among 250 genetically confirmed cases; 141/250 cases (56.4%) carried NHLRC1 variants; MS/MS genotype most common in NHLRC1 (53.2%); MS/PT ~28% (pondrelli2023prognosticvalueof pages 2-4, pondrelli2023prognosticvalueof pages 1-2)	NHLRC1 PT/PT genotype associated with shorter survival (HR 2.88, 95% CI 1.23–6.78) and trend to higher loss of autonomy (HR 2.03, 95% CI 0.75–5.56); homozygous p.Asp146Asn associated with a more favorable/milder course (pondrelli2023prognosticvalueof pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7)	DOI:10.1186/s13023-023-02880-6; https://doi.org/10.1186/s13023-023-02880-6 (pondrelli2023prognosticvalueof pages 1-2)
Disease-level architecture	Laforin–malin complex regulating glycogen metabolism	Lafora disease; progressive myoclonus epilepsy	Autosomal recessive Mendelian disorder	Extreme allelic heterogeneity with >150 causative variants reported overall; variants grouped as MS/MS, MS/PT, PT/PT for prognostic analyses	250 cases from 70 articles; 114 pathogenic variants total (67 EPM2A, 47 NHLRC1); about 90% of cases attributable to EPM2A or EPM2B/NHLRC1 in retrieved review/case literature (pondrelli2023prognosticvalueof pages 1-2, aggradi2023laforadiseasea pages 1-2)	Pathogenic variation in either gene disrupts glycogen regulation, causing polyglucosan/Lafora bodies; genotype has prognostic relevance, especially truncating NHLRC1 genotypes and p.Asp146Asn (pondrelli2023prognosticvalueof pages 1-2, aggradi2023laforadiseasea pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7)	DOI:10.1186/s13023-023-02880-6; https://doi.org/10.1186/s13023-023-02880-6; DOI:10.3390/brainsci13121679; https://doi.org/10.3390/brainsci13121679 (pondrelli2023prognosticvalueof pages 1-2, aggradi2023laforadiseasea pages 1-2)

Table: This table summarizes the two established causal genes for Lafora disease, their protein products, inheritance, variant classes, and the main genotype–phenotype findings from the 2023 patient-level meta-analysis. It is useful as a compact reference for disease-gene annotation and prognostic interpretation.

Key statistics from the 2023 meta-analysis: - 250 cases from 70 articles; 114 pathogenic variants total (67 EPM2A, 47 NHLRC1) (pondrelli2023prognosticvalueof pages 1-2) - Gene distribution: NHLRC1 in ~56% vs EPM2A in ~44% (pondrelli2023prognosticvalueof pages 2-4, zimmern2024progressivemyoclonusepilepsy pages 6-7) - Prognosis: NHLRC1 PT/PT genotype associated with shorter survival (HR 2.88, 95% CI 1.23–6.78) (pondrelli2023prognosticvalueof pages 1-2)

2.3 Non-genetic risk/protective factors; gene–environment interaction

No specific environmental risk factors, protective factors, or gene–environment interactions were captured in the retrieved evidence. In the current understanding from retrieved sources, LD is primarily driven by genetic disruption of glycogen homeostasis and secondary neuroinflammation. (duran2023roleofastrocytes pages 2-4, rubio2024beneficialeffectof pages 1-2)

3. Phenotypes

3.1 Core phenotype spectrum (human)

Clinical features described in recent clinical literature include: - Progressive myoclonic epilepsy: generalized tonic–clonic seizures, myoclonic jerks/spasms; visual phenomena/seizures can occur (aggradi2023laforadiseasea pages 1-2, aggradi2023laforadiseasea pages 4-6) - Progressive cognitive decline/dementia and neuropsychiatric symptoms (aggradi2023laforadiseasea pages 1-2, aggradi2023laforadiseasea pages 4-6) - Ataxia and other cerebellar signs may appear (aggradi2023laforadiseasea pages 4-6, zimmern2024progressivemyoclonusepilepsy pages 6-7)

Abstract quote (clinical): “It manifests as progressive myoclonus epilepsy and cognitive decline during adolescence.” (aggradi2023laforadiseasea pages 1-2)

3.2 Phenotype characteristics (onset, progression, severity)

Typical onset: adolescence; Italian cohort mean onset 13.4 years (zimmern2024progressivemyoclonusepilepsy pages 6-7)
Rapidly progressive course: cognitive decline commonly emerges 2–6 years after onset in one review/case synthesis (aggradi2023laforadiseasea pages 4-6)
Fatal outcome: often within ~10 years of onset (multiple recent sources; also expressed as 5–10 years after onset) (aggradi2023laforadiseasea pages 4-6, duran2023roleofastrocytes pages 1-2)

3.3 Natural history statistics and prognosis

From a large Italian natural-history cohort summarized in a 2024 PME scoping review: - Survival: 93% at 5 years, 62% at 10 years, 57% at 15 years (zimmern2024progressivemyoclonusepilepsy pages 6-7) - Median time to loss of autonomy: 6 years (zimmern2024progressivemyoclonusepilepsy pages 6-7) - Median survival: 11 years (zimmern2024progressivemyoclonusepilepsy pages 6-7)

From a 2023 patient-level meta-analysis (subset statistics reported): for EPM2A cases, “overall survival was 92% at 5 years, 59% at 10 years, and 49% at 15 years (mean age at death 22.4 years).” (pondrelli2023prognosticvalueof pages 2-4)

3.4 Suggested HPO terms (not exhaustive)

Based on the retrieved phenotype descriptions: - Seizures: HP:0001250 (Seizures); generalized tonic–clonic seizures HP:0002069 - Myoclonus: HP:0001336 (Myoclonus) - Progressive cognitive decline/dementia: HP:0001268 (Mental deterioration); dementia HP:0000726 - Ataxia: HP:0001251 (Ataxia) - Dysarthria: HP:0001260 (Dysarthria) (aggradi2023laforadiseasea pages 2-4) - Dysphagia: HP:0002015 (Dysphagia) (aggradi2023laforadiseasea pages 2-4)

Frequency-by-phenotype was not available in the retrieved excerpts; cohort-level frequency extraction would require additional full-text/registry sources.

4. Genetic/Molecular Information

4.1 Causal genes and variant architecture

LD is caused by biallelic pathogenic variants in EPM2A or NHLRC1/EPM2B. (pondrelli2023prognosticvalueof pages 1-2, donohue2023gys1antisensetherapy pages 1-2)

Variant architecture highlights: - Extreme allelic heterogeneity: “More than 150 different causative genetic variants” reported (pondrelli2023prognosticvalueof pages 1-2) - Variant types: missense/in-frame vs protein truncating (nonsense/frameshift/splice/deletions) (pondrelli2023prognosticvalueof pages 2-4)

4.2 Functional consequences (protein dysfunction)

Laforin deficiency affects glycogen phosphate homeostasis and/or glycogen architecture; malin deficiency disrupts regulation of glycogen-related proteins (e.g., PTG) and contributes to abnormal glycogen accumulation (mitra2023laforintargetsmalin pages 10-10, duran2023roleofastrocytes pages 8-10)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

No modifier genes, epigenetic mechanisms, or chromosomal abnormalities were captured in the retrieved evidence.

5. Environmental Information

No non-genetic environmental, lifestyle, or infectious causes were captured in the retrieved evidence, consistent with LD being a primarily genetic neurodegenerative epilepsy syndrome in these sources. (pondrelli2023prognosticvalueof pages 1-2)

6. Mechanism / Pathophysiology

6.1 Causal chain (current model)

A synthesis consistent across 2023–2024 sources: 1. Biallelic EPM2A or NHLRC1 variants → loss of laforin/malin complex function (pondrelli2023prognosticvalueof pages 1-2, duran2023roleofastrocytes pages 2-4) 2. Dysregulated glycogen metabolism → abnormal glycogen chain length/branching (and in some models hyperphosphorylation) → “transition of soluble glycogen to insoluble polyglucosan” (duran2023roleofastrocytes pages 8-10, mitra2023laforintargetsmalin pages 1-2) 3. Formation of Lafora bodies (polyglucosan aggregates) containing glycogen metabolism proteins and proteostasis/adaptor proteins including GS, ubiquitin, p62 (duran2023roleofastrocytes pages 1-2, duran2023roleofastrocytes pages 2-4) 4. Predominant accumulation in astrocytes (with neuronal inclusions also present) → network dysfunction, neuroinflammation, progressive seizures and neurodegeneration (duran2023roleofastrocytes pages 1-2, duran2023roleofastrocytes pages 2-4)

Abstract quote (astrocyte emphasis): “However, it was recently identified that most of these glycogen aggregates are present in astrocytes. Importantly, astrocytic Lafora bodies have been shown to contribute to pathology in Lafora disease.” (Feb 2023; Cells) (duran2023roleofastrocytes pages 1-2)

6.2 Cellular processes and pathways

Autophagy/endolysosomal dysfunction: LD inclusions and associated proteins implicate autophagic handling; autophagy impairment is described as secondary to glycogen accumulation and normalizes when glycogen accumulation is prevented in models (duran2023roleofastrocytes pages 2-4, duran2023roleofastrocytes pages 10-11)
Neuroinflammation: reactive astrocytes/microglia are described; a 2024 Epm2b-/- mouse study identified inflammatory pathway involvement including “mainly TNF and IL-6 signaling pathways” and demonstrated infiltration of peripheral immune cells (T-lymphocytes) (rubio2024beneficialeffectof pages 1-2)

6.3 Anatomical and cell-type localization

Lafora bodies accumulate in brain and peripheral tissues (e.g., liver, muscle, sweat glands) (aggradi2023laforadiseasea pages 4-6)
Cell types: both neuronal and astrocytic inclusions; “most LBs are present in astrocytes” with distinct morphologies (neuronal perinuclear nLBs vs corpora-amylacea-like astrocytic bodies) (duran2023roleofastrocytes pages 2-4)

6.4 Suggested ontology terms

GO biological process (examples): - Glycogen metabolic process (GO:0005977) - Glycogen biosynthetic process (GO:0005978) - Macroautophagy (GO:0016236) - Neuroinflammatory response (GO:0150076)

Cell Ontology (CL) suggestions: - Astrocyte (CL:0000127) - Neuron (CL:0000540) - Microglial cell (CL:0000129) - T cell (CL:0000084)

7. Anatomical Structures Affected

7.1 Organ/tissue systems

Central nervous system (primary): progressive epilepsy, cognitive decline, neurodegeneration (zimmern2024progressivemyoclonusepilepsy pages 6-7)
Peripheral tissues: Lafora bodies may be found in “brain, liver, muscle, and sweat glands” (aggradi2023laforadiseasea pages 4-6)

7.2 Suggested UBERON terms (examples)

Brain (UBERON:0000955)
Hippocampus (LBs enriched in astrocytes notably in hippocampus per review) (UBERON:0001954) (duran2023roleofastrocytes pages 2-4)
Skeletal muscle tissue (UBERON:0001134)
Skin (sweat glands/ducts) (UBERON:0002097)

8. Temporal Development

Onset: typically adolescence; previously healthy children develop seizures (duran2023roleofastrocytes pages 1-2)
Progression: progressive, rapid; median loss of autonomy 6 years and median survival 11 years (zimmern2024progressivemyoclonusepilepsy pages 6-7)

No remission patterns were captured in the retrieved evidence.

9. Inheritance and Population

9.1 Inheritance

Autosomal recessive, due to biallelic variants in EPM2A or NHLRC1. (pondrelli2023prognosticvalueof pages 1-2)

9.2 Epidemiology and geographic distribution

Prevalence estimates in retrieved sources: - “approximately four cases per one million individuals” (aggradi2023laforadiseasea pages 1-2) - Germany: 1.69 per 10 million (zimmern2024progressivemyoclonusepilepsy pages 6-7)

Geographic concentration (qualitative): “occurs most frequently in Mediterranean countries, South India, North Africa, and the Middle East.” (aggradi2023laforadiseasea pages 1-2)

Population-genetic details not captured in retrieved excerpts: incidence, carrier frequency, sex ratio, and explicit consanguinity rates.

10. Diagnostics

10.1 Clinical and electrophysiology

EEG findings include generalized/multifocal epileptiform discharges; in one case report EEG showed “multiple discharges across both brain hemispheres.” (aggradi2023laforadiseasea pages 1-2)

The 2024 scoping review highlights characteristic electrophysiology (photo-paroxysmal response, giant SSEP) though milder genotypes may show these less often. (zimmern2024progressivemyoclonusepilepsy pages 6-7)

10.2 Neuroimaging

MRI can be normal early: “Brain magnetic resonance imaging was unremarkable” in a genetically confirmed case (aggradi2023laforadiseasea pages 1-2); later disease may show widespread degeneration (aggradi2023laforadiseasea pages 4-6)

10.3 Biopsy

Axillary skin biopsy can detect PAS-positive inclusions in sweat duct cells but has “false-positive/false-negative limitations” (diagnostic pitfalls). (aggradi2023laforadiseasea pages 4-6)
Muscle biopsy may be atypical or lack Lafora bodies (as in a confirmed NHLRC1 case). (aggradi2023laforadiseasea pages 1-2, aggradi2023laforadiseasea pages 2-4)

10.4 Genetic testing

Genetic confirmation requires identifying biallelic pathogenic variants in EPM2A or EPM2B/NHLRC1; a case report used targeted NGS (clinical exome) plus Sanger confirmation and parental testing, with ACMG classification. (aggradi2023laforadiseasea pages 1-2, aggradi2023laforadiseasea pages 2-4)

10.5 Differential diagnosis

LD should be considered among progressive, refractory myoclonic epilepsies in children/young adults, and overlapping polyglucosan storage disorders are part of the differential. (aggradi2023laforadiseasea pages 1-2, aggradi2023laforadiseasea pages 6-7)

11. Outcome / Prognosis

LD is severe and progressive with high morbidity and premature mortality. Key quantitative outcomes from natural history are summarized above (Section 3.3). Prognosis can vary by genotype; truncating NHLRC1 genotypes are associated with shorter survival in the patient-level meta-analysis, and NHLRC1 p.Asp146Asn is associated with a more favorable course. (pondrelli2023prognosticvalueof pages 1-2, zimmern2024progressivemyoclonusepilepsy pages 6-7)

12. Treatment

12.1 Current clinical management (supportive)

There is no established disease-modifying therapy in routine practice in the retrieved sources. Management is supportive and symptom-focused (seizure control, supportive care), with diet-based interventions historically explored. (aggradi2023laforadiseasea pages 1-2, NCT00007124 chunk 1)

12.2 Experimental / translational therapeutics (2023–2024 emphasis)

A major contemporary strategy is substrate reduction—reducing glycogen synthesis in brain to prevent polyglucosan/Lafora body formation.

Type	Intervention	Mechanism/target	Population/model	Key endpoints/outcomes	Status	Dates	Sponsor	URL/DOI
Interventional clinical trial	ION283 intrathecal ASO (NCT06609889)	Antisense oligonucleotide therapy targeting abnormal glycogen synthesis pathway; efficacy endpoints based on EEG change from baseline to 2 years, including posterior dominant/background rhythms, sleep physiology, electrographic seizures, and epileptiform discharge counts	Patients aged 10–18 years with genetically confirmed EPM2A or EPM2B/NHLRC1 Lafora disease, LDPS score ≥9 and motor subscore ≥2	Safety and efficacy; EEG-based biomarkers over 2 years	Recruiting	Record excerpt current in 2024; version holder date 2026-04-24; start/completion dates not captured in excerpt	University of Texas Southwestern Medical Center; official: Berge Minassian, MD	https://clinicaltrials.gov/study/NCT06609889 (NCT06609889 chunk 2)
Observational clinical study	Natural History and Functional Status Study of Patients With Lafora Disease (NCT03876522)	Prospective natural-history study to define disease course, identify biomarkers, and establish outcome measures for future trials	33 participants, minimum age 5 years, genetically confirmed Lafora disease	Seizure frequency/duration, awake/sleep video EEG, Lafora Disease Performance/Clinical Performance Scales, cognition, gait/ataxia, caregiver burden, disability, QoL, blood/CSF biomarkers	Completed	2019-01-09 to 2022-04-01; 24-month assessments	Ionis Pharmaceuticals, Inc.	https://clinicaltrials.gov/study/NCT03876522 (NCT03876522 chunk 1)
Observational/proof-of-principle study	Ketogenic diet (NCT00007124)	Restrictive low-carbohydrate ketogenic diet intended to acutely modify brain/whole-body metabolism and possibly reduce disease manifestations	15 participants with relatively advanced Lafora disease; age ≥10 years; histologic or preferably genetic confirmation	Clinical scales plus MRI/MRS, LP, metabolic/endocrine testing, neuropsychology, EEG, EMG, SEP/VEP; 6-month diet with possible continuation to 12 months for responders	Completed	December 2000 to November 2002	National Institute of Neurological Disorders and Stroke (NINDS)	https://clinicaltrials.gov/study/NCT00007124 (NCT00007124 chunk 1)
Expanded access	VAL-1221 intravenous infusion every other week (NCT05930223; LEAP)	Enzyme-fusion/advanced therapeutic strategy intended to target Lafora body burden; protocol provides treatment access rather than formal efficacy trial	Up to 10 patients with genetically documented biallelic EPM2A or EPM2B variants; mid-stage disease, age 12–28 years	Access protocol; excerpt does not list formal endpoints/outcome measures	Available	Initial submission 2023-06-25; first posted 2023-07-05	Parasail, LLC	https://clinicaltrials.gov/study/NCT05930223 (NCT05930223 chunk 1)
Preclinical	Gys1-ASO intracerebroventricular antisense therapy	Reduces glycogen synthase 1 (Gys1) expression to lower brain glycogen synthesis and prevent formation of disease-driving Lafora bodies	Epm2b-/- (malin KO) mice; ICV dosing at 4, 7, and 10 months, sacrifice at 13 months	Decreased Gys1 mRNA/protein, reduced glycogen aggregation/Lafora body burden, fewer larger LBs, reduced epileptiform discharges; proof of concept that targeting glycogen synthesis can halt progression	Preclinical proof-of-concept	Published Oct 2023	Academic/industry collaboration; study authors included Ionis-associated ASO expertise	https://doi.org/10.1007/s13311-023-01434-9 (donohue2023gys1antisensetherapy pages 1-2, donohue2023gys1antisensetherapy pages 4-6)
Preclinical	Fingolimod	S1PR modulation to reduce reactive astrogliosis-derived neuroinflammation, stabilize BBB, and decrease T-lymphocyte brain infiltration; inflammatory pathways implicated include TNF and IL-6 signaling	Epm2b-/- mice treated from 3 months of age for 15 weeks; dose 0.5 mg/kg in drinking water	Reduced reactive astrocyte-derived neuroinflammation, decreased brain T-cell infiltration, and improved behavioral performance; more effective than dimethyl fumarate in this model	Preclinical	Published 2024	Academic study	https://doi.org/10.1007/s12035-023-03766-1 (rubio2024beneficialeffectof pages 1-2, rubio2024beneficialeffectof pages 2-4)

Table: This table summarizes the main retrieved Lafora disease clinical studies, expanded-access programs, and leading 2023–2024 preclinical therapeutic strategies. It is useful for quickly comparing mechanisms, populations/models, endpoints, and development status across the current translational landscape.

Key 2023–2024 developments from retrieved evidence: - GYS1 antisense (preclinical): intracerebroventricular Gys1-ASO at 4/7/10 months reduced Gys1 protein and Lafora body burden and reduced epileptiform discharges in Epm2b-/- mice (donohue2023gys1antisensetherapy pages 4-6) - ION283 (clinical trial): intrathecal ASO trial uses EEG biomarkers over 2 years as efficacy endpoints; recruiting ages 10–18 (NCT06609889) (NCT06609889 chunk 2) - Neuroinflammation modulation (preclinical): fingolimod reduced reactive astrocyte-derived neuroinflammation and T-lymphocyte infiltration and improved behavior in Epm2b-/- mice; inflammatory signaling implicated includes TNF and IL-6 (rubio2024beneficialeffectof pages 1-2, rubio2024beneficialeffectof pages 2-4) - VAL-1221 expanded access: IV 20 mg/kg every other week, up to 10 patients, genetically confirmed mid-stage disease (NCT05930223) (NCT05930223 chunk 1)

12.3 Suggested MAXO terms (examples)

Antisense oligonucleotide therapy (MAXO term family; label: antisense therapy)
Ketogenic diet therapy (dietary therapy)
Expanded access treatment program
Gene therapy / gene replacement therapy (preclinical in retrieved sources) (zafrapuerta2023genereplacementtherapy pages 21-24)

Specific MAXO IDs were not captured in retrieved sources; mapping would require ontology lookup.

13. Prevention

No primary prevention strategies beyond genetic counseling and family planning are detailed in retrieved sources. Genetic confirmation and family testing are implied by autosomal recessive inheritance and use of parental testing in case reports. (aggradi2023laforadiseasea pages 2-4)

14. Other Species / Natural Disease

Naturally occurring Lafora-like disease has been described in dogs and linked to NHLRC1 repeat expansions, including an “NHLRC1 repeat expansion in two beagles” and an “NHLRC1 homozygous dodecamer expansion in a Newfoundland dog,” with reports spanning multiple breeds (e.g., Basset hound, beagle, Newfoundland dog, miniature Wirehaired Dachshunds). (vincent2023retinalphenotypingof pages 9-10)

15. Model Organisms

15.1 Mammalian models (mouse)

Common murine models include Epm2a−/− (laforin KO) and Epm2b−/− (malin KO), which develop Lafora bodies and neurological phenotypes and are used for therapy testing (ASO, gene replacement). (donohue2023gys1antisensetherapy pages 1-2, zafrapuerta2023genereplacementtherapy pages 1-4)

Retinal biomarker/endpoint development (quantitative): In Epm2a−/− mice, retinal PASD staining showed inner plexiform layer Lafora body density 1743 ± 533/mm² at 10 months and 2615 ± 915/mm² at 14 months, while ERG parameters and retinal thickness were preserved, supporting retinal LB quantification as a potential monitoring readout in mice. (vincent2023retinalphenotypingof pages 1-2)

Neuromuscular model phenotype (2024): Laforin-deficient mice show neuromuscular junction dysfunction and motor neuron loss with an electrophysiological decrement reported as “(14.93±4.26%) at 50 Hz at the age of 5 months.” (shukla2024neuromuscularjunctiondysfunction pages 1-2)

15.2 Invertebrate models

A 2023 mechanistic review cites Drosophila and indicates forced neuronal glycogen accumulation can cause neuronal apoptosis, supporting glycogen excess as a driver of neurodegeneration. (duran2023roleofastrocytes pages 2-4)

Recent developments and expert analysis (2023–2024 priority)

Genotype–prognosis associations were quantitatively strengthened by a 2023 patient-level meta-analysis showing truncating NHLRC1 genotypes predict worse survival (HR 2.88), which is directly relevant for stratification and interpretation of disease-modifying trials. (pondrelli2023prognosticvalueof pages 1-2)
Cell-type re-framing toward astrocytes: a 2023 review emphasized that “most” Lafora bodies are astrocytic and that astrocytic aggregates contribute to pathology, shifting mechanistic and therapeutic attention to glial glycogen metabolism and glia-driven inflammation. (duran2023roleofastrocytes pages 1-2, duran2023roleofastrocytes pages 2-4)
Translational pipeline maturity: the existence of an Ionis-sponsored natural history study (NCT03876522) defining outcome measures and biomarkers, plus a recruiting ASO trial (NCT06609889) with EEG endpoints, indicates field movement from preclinical substrate reduction to biomarker-driven clinical development. (NCT03876522 chunk 1, NCT06609889 chunk 2)

Data gaps and limitations (from retrieved sources)

Orphanet/MeSH/ICD identifiers were not captured in retrieved evidence.
Incidence, carrier frequency, sex ratio, and explicit consanguinity statistics were not available in the retrieved excerpts.
Phenotype frequencies (percent affected) for individual HPO terms were not extractable from the retrieved excerpts; fuller cohort papers would be needed.

Key resources (URLs; access dates not applicable)

Open Targets disease page (MONDO_0009697): https://platform.opentargets.org/disease/MONDO_0009697 (aggradi2023laforadiseasea pages 1-2)
OMIM entry #254780: https://omim.org/entry/254780 (aggradi2023laforadiseasea pages 1-2)
Pondrelli et al., 2023 (Orphanet J Rare Dis; DOI 10.1186/s13023-023-02880-6): https://doi.org/10.1186/s13023-023-02880-6 (pondrelli2023prognosticvalueof pages 1-2)
Zimmern & Minassian, 2024 (Genes; DOI 10.3390/genes15020171): https://doi.org/10.3390/genes15020171 (zimmern2024progressivemyoclonusepilepsy pages 6-7)
Donohue et al., 2023 (Neurotherapeutics; DOI 10.1007/s13311-023-01434-9): https://doi.org/10.1007/s13311-023-01434-9 (donohue2023gys1antisensetherapy pages 4-6)
Duran, 2023 (Cells; DOI 10.3390/cells12050722): https://doi.org/10.3390/cells12050722 (duran2023roleofastrocytes pages 1-2)
Rubio et al., 2024 (Molecular Neurobiology; DOI 10.1007/s12035-023-03766-1): https://doi.org/10.1007/s12035-023-03766-1 (rubio2024beneficialeffectof pages 1-2)
ClinicalTrials.gov: NCT06609889 https://clinicaltrials.gov/study/NCT06609889 ; NCT03876522 https://clinicaltrials.gov/study/NCT03876522 ; NCT05930223 https://clinicaltrials.gov/study/NCT05930223 ; NCT00007124 https://clinicaltrials.gov/study/NCT00007124 (NCT06609889 chunk 2, NCT03876522 chunk 1, NCT05930223 chunk 1, NCT00007124 chunk 1)

References

(aggradi2023laforadiseasea pages 1-2): Carola Rita Ferrari Aggradi, Martina Rimoldi, Gloria Romagnoli, Daniele Velardo, Megi Meneri, Davide Iacobucci, Michela Ripolone, Laura Napoli, Patrizia Ciscato, Maurizio Moggio, Giacomo Pietro Comi, Dario Ronchi, Stefania Corti, and Elena Abati. Lafora disease: a case report and evolving treatment advancements. Brain Sciences, 13:1679, Dec 2023. URL: https://doi.org/10.3390/brainsci13121679, doi:10.3390/brainsci13121679. This article has 8 citations.
(pondrelli2023prognosticvalueof pages 1-2): Federica Pondrelli, Raffaella Minardi, Lorenzo Muccioli, Corrado Zenesini, Luca Vignatelli, Laura Licchetta, Barbara Mostacci, Paolo Tinuper, Craig W. Vander Kooi, Matthew S. Gentry, and Francesca Bisulli. Prognostic value of pathogenic variants in lafora disease: systematic review and meta-analysis of patient-level data. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02880-6, doi:10.1186/s13023-023-02880-6. This article has 16 citations and is from a peer-reviewed journal.
(NCT06609889 chunk 2): Berge Minassian. A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease. Berge Minassian. 2024. ClinicalTrials.gov Identifier: NCT06609889
(zimmern2024progressivemyoclonusepilepsy pages 6-7): Vincent Zimmern and Berge Minassian. Progressive myoclonus epilepsy: a scoping review of diagnostic, phenotypic and therapeutic advances. Genes, 15:171, Jan 2024. URL: https://doi.org/10.3390/genes15020171, doi:10.3390/genes15020171. This article has 20 citations.
(rubio2024beneficialeffectof pages 1-2): Teresa Rubio, Ángela Campos-Rodríguez, and Pascual Sanz. Beneficial effect of fingolimod in a lafora disease mouse model by preventing reactive astrogliosis-derived neuroinflammation and brain infiltration of t-lymphocytes. Molecular Neurobiology, 61:3105-3120, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03766-1, doi:10.1007/s12035-023-03766-1. This article has 5 citations and is from a peer-reviewed journal.
(NCT03876522 chunk 1): Natural History and Functional Status Study of Patients With Lafora Disease. Ionis Pharmaceuticals, Inc.. 2019. ClinicalTrials.gov Identifier: NCT03876522
(donohue2023gys1antisensetherapy pages 1-2): Katherine J. Donohue, Bethany Fitzsimmons, Ronald C. Bruntz, Kia H. Markussen, Lyndsay E.A. Young, Harrison A. Clarke, Peyton T. Coburn, Laiken E. Griffith, William Sanders, Jack Klier, Sara N. Burke, Andrew P. Maurer, Berge A. Minassian, Ramon C. Sun, Holly B. Kordasiewisz, and Matthew S. Gentry. Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease mouse model. Neurotherapeutics, 20:1808-1819, Oct 2023. URL: https://doi.org/10.1007/s13311-023-01434-9, doi:10.1007/s13311-023-01434-9. This article has 18 citations and is from a peer-reviewed journal.
(duran2023roleofastrocytes pages 2-4): Jordi Duran. Role of astrocytes in the pathophysiology of lafora disease and other glycogen storage disorders. Cells, 12:722, Feb 2023. URL: https://doi.org/10.3390/cells12050722, doi:10.3390/cells12050722. This article has 9 citations.
(pondrelli2023prognosticvalueof pages 2-4): Federica Pondrelli, Raffaella Minardi, Lorenzo Muccioli, Corrado Zenesini, Luca Vignatelli, Laura Licchetta, Barbara Mostacci, Paolo Tinuper, Craig W. Vander Kooi, Matthew S. Gentry, and Francesca Bisulli. Prognostic value of pathogenic variants in lafora disease: systematic review and meta-analysis of patient-level data. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02880-6, doi:10.1186/s13023-023-02880-6. This article has 16 citations and is from a peer-reviewed journal.
(aggradi2023laforadiseasea pages 4-6): Carola Rita Ferrari Aggradi, Martina Rimoldi, Gloria Romagnoli, Daniele Velardo, Megi Meneri, Davide Iacobucci, Michela Ripolone, Laura Napoli, Patrizia Ciscato, Maurizio Moggio, Giacomo Pietro Comi, Dario Ronchi, Stefania Corti, and Elena Abati. Lafora disease: a case report and evolving treatment advancements. Brain Sciences, 13:1679, Dec 2023. URL: https://doi.org/10.3390/brainsci13121679, doi:10.3390/brainsci13121679. This article has 8 citations.
(duran2023roleofastrocytes pages 1-2): Jordi Duran. Role of astrocytes in the pathophysiology of lafora disease and other glycogen storage disorders. Cells, 12:722, Feb 2023. URL: https://doi.org/10.3390/cells12050722, doi:10.3390/cells12050722. This article has 9 citations.
(aggradi2023laforadiseasea pages 2-4): Carola Rita Ferrari Aggradi, Martina Rimoldi, Gloria Romagnoli, Daniele Velardo, Megi Meneri, Davide Iacobucci, Michela Ripolone, Laura Napoli, Patrizia Ciscato, Maurizio Moggio, Giacomo Pietro Comi, Dario Ronchi, Stefania Corti, and Elena Abati. Lafora disease: a case report and evolving treatment advancements. Brain Sciences, 13:1679, Dec 2023. URL: https://doi.org/10.3390/brainsci13121679, doi:10.3390/brainsci13121679. This article has 8 citations.
(mitra2023laforintargetsmalin pages 10-10): Sharmistha Mitra, Baozhi Chen, Peixiang Wang, Erin E. Chown, Mathew Dear, Dikran R. Guisso, Ummay Mariam, Jun Wu, Emrah Gumusgoz, and Berge A. Minassian. Laforin targets malin to glycogen in lafora progressive myoclonus epilepsy. Disease Models & Mechanisms, Jan 2023. URL: https://doi.org/10.1242/dmm.049802, doi:10.1242/dmm.049802. This article has 19 citations and is from a domain leading peer-reviewed journal.
(duran2023roleofastrocytes pages 8-10): Jordi Duran. Role of astrocytes in the pathophysiology of lafora disease and other glycogen storage disorders. Cells, 12:722, Feb 2023. URL: https://doi.org/10.3390/cells12050722, doi:10.3390/cells12050722. This article has 9 citations.
(mitra2023laforintargetsmalin pages 1-2): Sharmistha Mitra, Baozhi Chen, Peixiang Wang, Erin E. Chown, Mathew Dear, Dikran R. Guisso, Ummay Mariam, Jun Wu, Emrah Gumusgoz, and Berge A. Minassian. Laforin targets malin to glycogen in lafora progressive myoclonus epilepsy. Disease Models & Mechanisms, Jan 2023. URL: https://doi.org/10.1242/dmm.049802, doi:10.1242/dmm.049802. This article has 19 citations and is from a domain leading peer-reviewed journal.
(duran2023roleofastrocytes pages 10-11): Jordi Duran. Role of astrocytes in the pathophysiology of lafora disease and other glycogen storage disorders. Cells, 12:722, Feb 2023. URL: https://doi.org/10.3390/cells12050722, doi:10.3390/cells12050722. This article has 9 citations.
(aggradi2023laforadiseasea pages 6-7): Carola Rita Ferrari Aggradi, Martina Rimoldi, Gloria Romagnoli, Daniele Velardo, Megi Meneri, Davide Iacobucci, Michela Ripolone, Laura Napoli, Patrizia Ciscato, Maurizio Moggio, Giacomo Pietro Comi, Dario Ronchi, Stefania Corti, and Elena Abati. Lafora disease: a case report and evolving treatment advancements. Brain Sciences, 13:1679, Dec 2023. URL: https://doi.org/10.3390/brainsci13121679, doi:10.3390/brainsci13121679. This article has 8 citations.
(NCT00007124 chunk 1): Ketogenic Diet in Lafora Disease. National Institute of Neurological Disorders and Stroke (NINDS). 2000. ClinicalTrials.gov Identifier: NCT00007124
(NCT05930223 chunk 1): Intravenous VAL-1221 Lafora Expanded Access Protocol. Parasail, LLC. ClinicalTrials.gov Identifier: NCT05930223
(donohue2023gys1antisensetherapy pages 4-6): Katherine J. Donohue, Bethany Fitzsimmons, Ronald C. Bruntz, Kia H. Markussen, Lyndsay E.A. Young, Harrison A. Clarke, Peyton T. Coburn, Laiken E. Griffith, William Sanders, Jack Klier, Sara N. Burke, Andrew P. Maurer, Berge A. Minassian, Ramon C. Sun, Holly B. Kordasiewisz, and Matthew S. Gentry. Gys1 antisense therapy prevents disease-driving aggregates and epileptiform discharges in a lafora disease mouse model. Neurotherapeutics, 20:1808-1819, Oct 2023. URL: https://doi.org/10.1007/s13311-023-01434-9, doi:10.1007/s13311-023-01434-9. This article has 18 citations and is from a peer-reviewed journal.
(rubio2024beneficialeffectof pages 2-4): Teresa Rubio, Ángela Campos-Rodríguez, and Pascual Sanz. Beneficial effect of fingolimod in a lafora disease mouse model by preventing reactive astrogliosis-derived neuroinflammation and brain infiltration of t-lymphocytes. Molecular Neurobiology, 61:3105-3120, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03766-1, doi:10.1007/s12035-023-03766-1. This article has 5 citations and is from a peer-reviewed journal.
(zafrapuerta2023genereplacementtherapy pages 21-24): Luis Zafra-Puerta, Daniel F. Burgos, Nerea Iglesias-Cabeza, Juan González-Fernández, Gema Sánchez-Martín, Marina P. Sánchez, and José M. Serratosa. Gene replacement therapy for lafora disease in the epm2a-/- mouse model. bioRxiv, Dec 2023. URL: https://doi.org/10.1101/2023.12.14.571636, doi:10.1101/2023.12.14.571636. This article has 1 citations.
(vincent2023retinalphenotypingof pages 9-10): Ajoy Vincent, Kashif Ahmed, Rowaida Hussein, Zorana Berberovic, Anupreet Tumber, Xiaochu Zhao, and Berge A. Minassian. Retinal phenotyping of a murine model of lafora disease. Genes, 14:854, Mar 2023. URL: https://doi.org/10.3390/genes14040854, doi:10.3390/genes14040854. This article has 1 citations.
(zafrapuerta2023genereplacementtherapy pages 1-4): Luis Zafra-Puerta, Daniel F. Burgos, Nerea Iglesias-Cabeza, Juan González-Fernández, Gema Sánchez-Martín, Marina P. Sánchez, and José M. Serratosa. Gene replacement therapy for lafora disease in the epm2a-/- mouse model. bioRxiv, Dec 2023. URL: https://doi.org/10.1101/2023.12.14.571636, doi:10.1101/2023.12.14.571636. This article has 1 citations.
(vincent2023retinalphenotypingof pages 1-2): Ajoy Vincent, Kashif Ahmed, Rowaida Hussein, Zorana Berberovic, Anupreet Tumber, Xiaochu Zhao, and Berge A. Minassian. Retinal phenotyping of a murine model of lafora disease. Genes, 14:854, Mar 2023. URL: https://doi.org/10.3390/genes14040854, doi:10.3390/genes14040854. This article has 1 citations.
(shukla2024neuromuscularjunctiondysfunction pages 1-2): Monica Shukla, Deepti Chugh, and Subramaniam Ganesh. Neuromuscular junction dysfunction in lafora disease. Disease Models & Mechanisms, Oct 2024. URL: https://doi.org/10.1242/dmm.050905, doi:10.1242/dmm.050905. This article has 5 citations and is from a domain leading peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Definition and current understanding

1.2 Key identifiers, synonyms, and data provenance

2. Etiology

2.1 Disease causal factors

2.2 Genetic risk factors (causal variants)

2.3 Non-genetic risk/protective factors; gene–environment interaction

3. Phenotypes

3.1 Core phenotype spectrum (human)

3.2 Phenotype characteristics (onset, progression, severity)

3.3 Natural history statistics and prognosis

3.4 Suggested HPO terms (not exhaustive)

4. Genetic/Molecular Information

4.1 Causal genes and variant architecture

4.2 Functional consequences (protein dysfunction)

4.3 Modifier genes / epigenetics / chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (current model)

6.2 Cellular processes and pathways

6.3 Anatomical and cell-type localization

6.4 Suggested ontology terms

7. Anatomical Structures Affected

7.1 Organ/tissue systems

7.2 Suggested UBERON terms (examples)

8. Temporal Development

9. Inheritance and Population

9.1 Inheritance

9.2 Epidemiology and geographic distribution

10. Diagnostics

10.1 Clinical and electrophysiology

10.2 Neuroimaging

10.3 Biopsy

10.4 Genetic testing

10.5 Differential diagnosis

11. Outcome / Prognosis

12. Treatment

12.1 Current clinical management (supportive)

12.2 Experimental / translational therapeutics (2023–2024 emphasis)

12.3 Suggested MAXO terms (examples)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

15.1 Mammalian models (mouse)

15.2 Invertebrate models

Recent developments and expert analysis (2023–2024 priority)

Data gaps and limitations (from retrieved sources)

Key resources (URLs; access dates not applicable)